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I.1. Pulmonary arterial hypertension (PAH) 
 
Definition, classification, epidemiology. Pulmonary arterial hypertension (PAH) 
represents a severe condition associated with a poor prognosis, a high rate of mortality and 
limited survival[145]. Clinically defined as an elevation of mean pulmonary arterial pressure to 
levels higher than 25 mmHg at rest and/or 30 mmHg during exercise[25;145], PAH is 
characterized by a progressive increase in pulmonary vascular resistance, that leads to a gradual 
rise in pulmonary arterial pressure, to right ventricular failure and ultimately death[74;145]. PAH 
is included in the classification accepted in Dana Point in 2008, as one of the subcategories of 
pulmonary hypertension (PH) (see Table 1)[163] and comprises a) the idiopathic (formerly 
known as “primary”) form- IPAH (PAH without established etiology), b) the familial form 
(FPAH) and c) pulmonary hypertension associated with a number of other conditions, such as 
collagen vascular disease, congenital systemic to pulmonary shunts, portal hypertension or HIV 
infection. Furthermore, pulmonary veno-occlusive disease (PVOD), pulmonary capillary 
haemangiomatosis (PCH) and persistent pulmonary hypertension of the newborn (PPHN) are at 
present included in the group of pulmonary arterial hypertension.  
IPAH affects twice as many women as men, most often in the third and forth decades of 
life, with a mean age of diagnosis of 36 years. The disease is rarely diagnosed and treated from 
the onset of the clinical manifestation, which has as a consequence the rapid progression of the 
disease and a medial survival interval of 2-8 years from the moment of diagnosis[145]. The 
familial form of the disease accounts for approximately 6% of the total cases of PAH[149], is 
characterized by an autosomal dominant inheritance and recent investigations have connected it 
to mutations of genes encoding the TGF-β receptor family members BMPRII (responsible of at 
least 70% of FPAH cases and also of 10-20% of IPAH cases) and activin receptor-like kinase 1 
(ALK-1)[99;120]. Secondary PAH, on the other hand, can be induced by the ingestion of several 
appetite suppressants like aminorex fumarate or dexfenfluramine, by the ingestion of toxic 
rapeseed oil (as these factors have been incriminated in several epidemics of PAH in the 
1960’s)[1;56;92]or by a number of diseases that predispose to PAH[174]. 
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Table 1. Classification of pulmonary hypertension (Dana Point, 2008) (after Simonneau et al., 2009 [163])   
 
1. Pulmonary arterial hypertension (PAH) 
1.1. Idiopathic PAH  
1.2. Heritable 
1.2.1. BMPR2 
1.2.2. ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia) 
1.2.3. Unknown 
1.3. Drug- and toxin- induced 
1.4. Associated with 
1.4.1. Connective tissue disorders 
1.4.2. HIV infection 
1.4.3. Portal hypertension 
1.4.4. Congenital heart diseses 
1.4.5. Schistosomiasis 
1.4.6. Chronic hemolytic anemia 
1.5. Persistent pulmonary hypertension of the newborn 
1’.  Pulmonary veno-occlusive (PVOD) and/or pulmonary capillary hemangiomatosis (PCH) 
2. Pulmonary hypertension owing to left heart disease 
2.1. Systolic dysfunction 
2.2. Diastolic dysfunction 
2.3. Vascular disease 
3. Pulmonary hypertension owing to lung diseases and/or hypoxia 
3.1. Chronic obstructive pulmonary disease 
3.2. Interstitial lung disease 
3.3. Other pulmonary diseases with mixed restrictive and obstructive pattern 
3.4. Sleep-disordered breathing 
3.5. Alveolar hypoventilation disorders 
3.6. Chronic exposure to high altitude 
3.7. Developmental abnormalities 
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. Pulmonary hypertension with unclear multifactorial mechanisms 
5.1. Hematologic disorders: myeloproliferative disorders, splenectomy 
5.2. Systemic disorders: sarcoidosis, pulmonary Langerhans cell histiocytosis: 
lymphangioleiomyomatosis, neurofibromatosis, vasculitis 
5.3. Metabolic disorders: glycogen storage disease, Gaucher disease, thyroid disorders 
5.4. Others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis 
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Diagnosis. Most patients in early phases of PAH present with nonspecific symptoms 
like fatigue and dyspnea on exertion, which delays the diagnosis many times by months or years. 
Fatigue, chest pain, syncope, peripheral edema or abdominal distension are manifestations of the 
already advanced disease, reflecting the inability of the heart to adjust to the necessary increase 
in cardiac output during activity and the progressive right heart failure[145]. 
Transthoracic echocardiography is an important non-invasive diagnostic test that can be 
used in all PAH patients and can give important information regarding the dimensions of the 
chambers of the heart, the estimated systolic pulmonary arterial pressure, possible intracardiac 
shunts or defects leading to PAH[145]. The diagnosis suggested by echocardiography must be 
confirmed by right heart catheterization, which remains the main tool for the diagnosis of 
PAH[115;145]. Other non-invasive tests include the 6-min-walk test (which correlates inversely 
with the functional class severity), chest radiographs (which can show enlarged pulmonary 
arteries and right heart dilation), electrocardiograms (which can show right axis deviation and 
right ventricular hypertrophy) and ventilation-perfusion testing (especially for the detection of 
chronic thromboembolism) or computer tomography scanning of the chest[25;115;145].  
Morphological changes. In addition to vasoconstriction, the disease is associated with 
complex and progressive morphological changes involving all layers of the vessel wall[74]. This 
process affects mainly small pulmonary arteries and arterioles, in which the neomuscularization 
of peripheral normally nonmuscularized vessels, the development of neointima and plexiform 
lesions, adventitial proliferation, as well as in situ thrombosis represent main histopathologic 
features[74;120].  
Although the exact initiating events of PAH remain unclear, at present it is believed that 
endothelium injury (caused by shear stress, hypoxia, inflammation, drugs or toxins) is the first 
step in the progression of PAH[120]. The damaging factor can induce, especially on a background 
of genetic susceptibility, an imbalance between endothelium-derived vasodilator (prostacyclin, 
nitric oxide) and vasoconstrictor agents (thromboxane, endothelin-1, angiotensin II), with the 
predominance of vasoconstrictive proliferating agents[74;120]. The consequence is variable 
vasoconstriction, the intense proliferation of vascular smooth muscle cells (with distal 
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extension), the formation of neointima, the proliferation and migration of adventitial fibroblasts 
into the media and ultimately the intima, as well as the increase in the neovascularisation of vasa 
vasorum[74]. Thus, the increase in pulmonary arterial pressure triggers a vicious cycle by 
stimulating through endothelial cell injury the deposition of collagen and the proliferation of 
smooth muscle cells, which further increase the pulmonary vascular resistance[91]. 
Neointima is a typical histological change of PAH and represents a new layer of 
myofibroblasts and extracellular matrix localized between the endothelium and lamina elastica 
interna. Due to its positive staining for α-smooth muscle actin[83], it is supposed that the cells 
composing it represent mainly a specialized subpopulation of smooth muscle cells. However, the 
possibility of a fibroblastic or endothelial origin can not be totally ruled out, since fibroblasts 
can migrate into the medial layer and transform into smooth muscle cells (SMCs)[172]  and 
endothelial cells can also transdifferentiate into smooth muscle cells (endothelial-mesenchymal 
transdifferentiation) when stimulated with growth factors such as PDGF[52]. 
Plexiform lesions, formed by the clonal expansion of endothelial cells supported by a 
stroma of matrix proteins and myofibroblasts represent another hallmark of human PAH 
(detected in 80% of PAH cases[120]), which could unfortunately not be reproduced in any of the 
existing animal models[74]. Most often they are localized distal to the area of obliterative 
thickening, in pre-and intra-acinar pulmonary arteries and at arterial branching points. Arteritis 
associated with fibrinoid necrosis and inflammatory cell infiltration as well as dilatation lesions 
localized distal to plexiform lesions, which can lead to pulmonary haemorrhage and scarring, 
have also been mentioned[132]. 
Along with the structural modifications of the vessel wall, the damage of endothelium 
generates a thrombogenic surface, which triggers a continuous process of intravascular 
coagulation. Normally, the endothelium maintains an equilibrium between thrombosis (induced 
by activating factor X, the extrinsic pathway of coagulation or by the release of von Willebrand 
factor and plasminogen activator inhibitor-1 {PAI-1}) and the inhibition of thrombosis and 
promotion of fibrinolysis (by producing nitric oxide, prostacyclin, thrombomodulin or tissue 
plasminogen activator {t-PA})[12]. However, marked elevations of circulating PAI-1 and von 
Willebrand factor as well as reduced soluble thrombomodulin levels were described in patients 
with severe PAH, suggesting an impaired process of fibrinolysis and increased thrombosis[194]. 
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In addition, inflammatory cells seem to be involved in some forms of human or animal 
PH, including monocrotaline (MCT)-treated rats, as suggested by the high levels of 
inflammatory cell infiltrates around plexiform lesions (mainly macrophages, mast cells, T and B 
lymphocytes). Also, the elevated circulating levels of proinflammatory cytokines IL1 and 
IL6[40;121], of inflammatory chemokines like macrophage inflammatory protein-1α, RANTES, 
as well as of P-selectin (a glycoprotein involved in neutrophil adhesion to the endothelium and 
platelet activation), have been mentioned to play a role in the inflammatory process[6;41;47;155].  
Current treatment of PAH. Until the last decade, before the development of new 
specific therapies, the 1-year survival rate of patients diagnosed with PAH was 68%, the 5-year 
survival rate was approximately 34% and the common course of the disease was a rapid 
progression towards right heart failure and death[145].  
For a long period of time, the classical therapy of PAH patients included the 
administration of anticoagulants, calcium-channel blockers and prostacyclins (intravenous 
epoprostenol)[149]. Anticoagulant therapy with warfarin has been shown to improve survival in 
patients with IPAH[81], and is also recommended in all patients with thromboembolic PH[25]  
due to its capacity to prevent in situ thrombosis and pulmonary embolism. Calcium-channel 
blockers (like nifedipine or diltiazem) can be used only in those patients having a positive 
response to the vasodilator challenge, which unfortunately represent only 10% of IPAH patients 
and even less in other forms of PAH[166]. Epoprostenol (a synthetic prostacyclin) is a product 
that causes vasodilation and inhibits vascular proliferation and platelet aggregation and can 
improve exercise tolerance, hemodynamic parameters, the quality of life and survival in IPAH 
patients when administered intravenously[25]. Its short half-life and, as a consequence, the 
requirement of continuous infusion remain, however, important drawbacks of this therapy.  
As a response to the need for products with better availability and easier delivery, longer-
acting prostacyclin analogs like treprostinil, iloprost and beraprost have been created and are 
available for intravenous, inhaled or oral use[25]. All these agents can significantly improve 
hemodynamic parameters and exercise tolerance and are at present considered as therapy for 
IPAH patients in functional classes II and III[71].  
Based on the potent effect of endothelin as vasoconstrictor and mitogen, oral endothelin-
1 receptor A and B antagonists like bosentan, ambrisentan and sitaxsentan have been recently 
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introduced. At present, due to its effect of improving survival, hemodynamics, exercise capacity 
and dyspnea, bosentan is recommended in clinical use for patients with stable functional class III 
or IV[25;145] and the other two agents have also shown promising results by improving the 
exercise capacity and hemodynamics in 12- to 18- week clinical trials[8;55].  
Furthermore, PDE-5 inhibitors like sildenafil and tadalafil increase the effects of locally 
produced NO, thus representing potent vasodilators. They have proven their efficacy not only in 
experimental PH but also in human patients, in which they improved the symptoms, 
hemodynamic parameters, 6-min walk distance and 1-year survival[25]. 
 
I.2. Animal models of pulmonary hypertension 
 
In order to gain more knowledge about the pathophysiological mechanisms of pulmonary 
hypertension, several animal models have been introduced, some of them resembling very 
closely the human disease. However, none of them is able to fully mimic all characteristic 
features of human PAH patients.  
Pulmonary hypertension can be experimentally induced by ligating ductus arteriosus in 
fetal lambs[2], by exposing rats to hyperoxia[139], by repeated microembolisations of small 
pulmonary vessels[161] or by genetically engineering animals (5-HTT overexpressing mice[62], 
ET-B receptor deficient rats[77], BMPRII +/- mice[11], IL6[170] or Ang-1[39] overexpressing 
animals). However, the monocrotaline and hypoxia induced models of pulmonary hypertension 
still remain the most used models, due to their highest similarity to the human condition.  
a. The hypoxia model is based on the observations that the reduction of oxygen 
concentration leads, after a short exposure, to acute pulmonary vasoconstriction whereas 
prolonged hypoxia induces medial and adventitial hyperplasia in pulmonary arterial walls[187]. 
Normo and hypobaric hypoxia have been used to induce PH in rats, mice or neonatal calves and 
the hypoxic model is considered a very useful tool for studying the human disease due to its high 
predictability and reproducibility. In rats, it is characterized by the muscularization of small, 
normally non-muscular arteries in the alveolar wall, the increased thickening of already 
muscularized pulmonary arteries and by an early and persistent vascular inflammatory response. 
All these changes lead to a 2-fold increase of mean pulmonary arterial pressure (PAP) in rats 
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subjected to hypoxia for 2 weeks, as well as to the development of right ventricular hypertrophy. 
On the other hand, in mice exposed to chronic hypoxia -although elevations in pulmonary artery 
pressure were observed- the vascular remodeling process was less significant than in rats[173], 
whereas neonatal calves exposed to chronic hypobaric hypoxia seem to be more sensitive to this 
stimulus and to develop severe PH with more extensive vascular remodeling than that observed 
in rats or mice[171]. Unlike in the human disease, however, which does not respond to oxygen 
therapy, the hypoxia-induced PH is fully reversible in rat and mice after the return to normoxic 
conditions and is not associated with the development of neointima or plexiform lesion 
formation. 
b. Introduced more than 40 years ago, the MCT model is based on the complex 
effects triggered by the administration of a pyrrolizidine alkaloid- monocrotaline (Figure 1) 
obtained from the seeds of a plant (Crotalaria spectabilis). It is characterized by the rapid 
development of severe pulmonary disease in the absence of intrinsic heart disease. In humans, 
MCT is a recognized as a carcinogen and it is suspected to have gastrointestinal, liver, 
cardiovascular, kidney and respiratory toxicity. Whereas some animal species (e.g. mice) are 
resistant to this toxic agent and do not develop PH in time, others (rats, turkeys, pigs and sheep) 
react to this compound and present lung damage[42;104]. In rats, after the typical administration 
as a single injection (60 mg/kg) intraperitoneally or subcutaneously, monocrotaline is 
metabolized in the liver mainly by the cytochrome P450 to the reactive MCT pyrrole (MCTP), 
the initial dehydrogenation product of MCT. After a short-term stabilization due to the binding 
to red blood cells and transportation through the circulation to the lungs, MCTP produces lung 
vascular endothelium injury, the early event in the development of the disease[129].  
In adult rats, the initial injection leads within a few hours to the injury of the vascular 
endothelium, followed by the extravascular leakage of proteases that act on extracellular matrix 
components and trigger the early inflammatory response[173]. After the initial events, a phase of 
increased reactivity to vasoconstrictor agents occurs, followed by a progressive thickening of the 
pulmonary arterial medial layer, even after the complete excretion of the alkaloid. 
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Figure 1. Chemical structure of monocrotaline and its metabolite (after Roth R.  and Ganey P., 1988 [148]) 
 
 
Studies performed in the MCT model have evidenced at day four a process of endothelial 
cell injury and fragmentation of the internal elastic lamina, by day eight the extension of muscle 
into peripheral nonmuscular arteries without elevation in PAP and at day twelve significant 
elevations in PAP and vascular resistance as well as right ventricular hypertrophy and further 
progression of structural lung changes[85]. Pulmonary sequestration of platelets in thrombi and 
moderate thrombocytopenia as well as an early and sustained rise in lung polyamine levels[126], 
increased collagen synthesis in pulmonary arteries[89], dilated lymphatic vessels, alveolar 
edema[176] and hypertrophy of pulmonary veins[196] have also been described during the 
progression of the disease. 
Differences between rat strains and even within the same strains have been noted 
regarding the sensitivity and response to MCT administration. Furthermore, age is another factor 
influencing the progression of the disease in rats: after the initial manifestations induced by the 
injection of MCT, adult rats continue to develop progressive vascular changes and pulmonary 
hypertension, whereas infant rats show spontaneous regression of the disease[85;183]. 
Although plexiform lesions could not be identified in this model, other characteristics 
like initial pulmonary vascular endothelial cell injury, development of thromboemboli, 
perivascular inflammation, necrotising arteritis, neomuscularization of small pulmonary arteries, 
decrease of peripheral arterioles number and right heart hypertrophy, also present in the course 
of the human disease, make the MCT model a very valuable tool for the investigation of the 
inner mechanisms of PH and for the evaluation of efficacy of different regimens. 
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I.3. The EGF pathway 
 
I.3.1. Overview of the EGF pathway 
 
Epidermal growth factor (EGF) is a growth factor that plays an important role in the 
regulation of cell growth, proliferation and differentiation. It belongs to the family of EGF-like 
molecules, together with TGF-α, heparin binding-EGF (HB-EGF), amphiregulin, epiregulin, 
betacellulin, neuregulins 1,2,3,4 and the pox virus growth factors, which have highly similar 
structural and functional characteristics[13;21;75]. These EGF-like molecules have the common 
characteristics of binding with high affinity to the EGF receptor and producing mitogenic 
responses in EGF-sensitive cells.  
Epidermal growth factor. Human epidermal growth factor originates from a large 
precursor protein of 1207 aminoacids encoded by the gene found in humans on chromosome 
4q25-q27, which needs enzymatic trimming before activation[59]. Although in the mouse 
submaxillary gland the precursor is rapidly processed to the active form of the growth factor, in 
some cells of the kidney the precursor can accumulate without being processed 
intracellularly[140]; in these cases, the prepro-EGF can exist as a glycosilated membrane protein 
and retains the EGF-like biological activities[113]. 
Early studies have shown that epidermal growth factor is a polypeptide of 53 
aminoacids, produced in large quantities in the granular convoluted tubule cells from the male 
mouse submandibular gland, the first organ where it was found and the richest biological source 
of EGF[60]. In humans, EGF has been found in varying concentrations in milk, saliva, urine, 
plasma, cerebrospinal fluid and most other body fluids. Although cells from a wide range of 
organs can produce it, the main source for EGF synthesis and release are the distal tubules of the 
kidney, the parotid and submaxillary glands, Brunner’s glands (submucosal glands located 
throughout the duodenum), pancreas, pituitary gland, nervous system as well as the thyroid and 
mammary glands[87;133;181].  
Receptors. EGF receptors are specific, high-affinity but low-capacity receptors encoded 
by genes located on the human chromosomes 7 (7p14-p12)-for EGFR[190], 17 (17q21-q22)-for 
HER2[34], 12 (12q13)-for HER3[94] and 2 (2q33.3-34)-for HER4[202], respectively. Their 
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presence has been identified throughout the embryonic development in several organs from the 
human and murine fetuses (brain, placenta, intestine, lung, liver, kidney)[3;118;137], suggesting 
their role in the organogenesis of mammalians. In adult humans, almost all types of tissues 
express them and in normal cells their expression ranges from 40.000 to 100.000 copies/cell[20].  
The four related EGF receptors, EGFR1 (ErbB1, HER1), HER2/c-neu (ErbB-2), ErbB3 
(HER3) and ErbB4 (HER4) belong to the ErbB family of receptors and can be activated not only 
by EGF, but also by the other EGF-like growth factors, especially TGF-α (Figure 2)[75]. 
 
Figure 2. ERBB receptors and ligands (after Hynes N.E. and Lane H.A., 2005 [75]). 1,2,3 and 4 represent HER 1, 
2, 3 and 4 respectively. 
 
The receptor is found on the membrane of cells and consists of a single chain with three 
main parts: the EGF-binding domain (the outer part), the transmembrane domain and the 
tyrosine-kinase domain (the inner part) (Figure 3). In the absence of the ligand, the EGF receptor 
folds into an inactive form that cannot dimerize; binding of EGF to the globular parts of the 
outer domain of the receptor triggers the release of one of the long cysteine-rich sections, 
allowing the receptor to dimerize with other similar or different types of receptors (homo- or 
heterodimerization). As a particularity, ErbB2 has even in the absence of a ligand a 
conformation resembling the ligand-activated state, which makes ligand binding impossible 
(thus the inability of ErbB2 to bind any ligand) and renders it as the main dimerization partner 
for the other activated ErbB receptors[123]. Furthermore, HER3 is the only ErbB receptor that 
does not have an active kinase domain and cannot convey the signal into the cell but it can form 
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heterodimers with other EGF receptors, the ErbB-2/ErbB-3 heterodimers being the most potent 
regarding cell proliferation[29]. 
 
Figure 3. Structure of the EGF receptor (after Goodsell D., 2003 [58]). 
 
 
Dimerization brings the two tyrosine kinase domains of the receptor closer to each other, 
allowing them to add phosphates groups to the tyrosine residues on the neighboring chain (the 
process of activation of the intrinsic protein tyrosine kinase and tyrosine autophosphorylation). 
These newly phosphorylated sites, located mainly at the C-terminal tail of the receptor recruit 
various signaling proteins inside the cell, initiating the signaling cascades that ultimately lead to 
DNA synthesis and cellular growth[58].  
Intracellular pathways. The dimerization and activation of EGF receptors leads to the 
activation of the Ras-Raf-MAPK pathway (which causes the phosphorylation of the c-Fos 
transcription factor) and of STAT-1 and STAT-3 transcription factors, both of them ultimately 
leading to proliferation. The proliferative effects of EGF are also signaled through the PI3K/Akt  
pathway, which regulates processes like gene expression, cell survival or angiogenesis[69;157] 
INTRODUCTION 
___________________________________________________________________________________ 
 
 
New  Therapeutic Strategies for the Treatment of Experimental Pulmonary Hypertension:  
Role of the Epidermal Growth Factor 
 
17
and through PLCγ, which hydrolyzes PIP2, mobilizes Ca2+ from the intracellular stores 
(through IP3) and activates PKC (through 1,2-diacylglycerol), leading to NF-KB dependent 
transcription[80] (Figure 4).  
 
Figure 4. Signaling pathways activated by EGFR (according to Scaltriti M. and Baselga J., 2006[157]) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Effects. Due to its important role in the regulation of cell growth, proliferation and 
differentiation, EGF is a strong mitogen especially, but not exclusively, for epithelial cells. Early 
studies on EGF function in the intact animal demonstrated its stimulatory effect on epidermal 
proliferation and its inhibitory effect on gastric acid secretion[21]. Furthermore, it has been 
shown that EGF also influences the proliferation of fibroblasts[98], human glial cells[117] or 
extracellular matrix (by regulating the synthesis of fibronectin, collagen or 
glycosaminoglycans)[66;110;189]. It also plays an important role in the normal function of the 
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central nervous and endocrine system by modulating the synthesis of a number of hormones and 
can influence the activity of some types of GABAergic and dopaminergic neurons. The 
involvement of EGF in the central nervous system (CNS) functions is demonstrated by the 
inhibitory effect it has on food intake in rats after intracerebroventricular injection[134] as well as 
by the reduced serum EGF levels in schizophrenic patients[54]. Although sialoadenectomy seems 
to have no effect on testosterone and FSH levels despite the important decrease of EGF 
circulating levels, results published by Tsutsumi et al.[186] prove the involvement of EGF in the 
normal function of reproductive organs in humans.  They demonstrate an important decrease of 
the number of spermatids in the testis and of mature sperm in the epididymis after 
sialoadenectomy and the correction of these changes by administrating EGF. 
Due to the fact that the main function of EGF is the maintenance of mucosal integrity 
and the acceleration of regeneration of the epithelial cells[125], different topic products 
containing EGF have already been marketed for wound healing in burn treatment creams.  
Positive effects have been shown after topical applications of EGF in diabetic foot ulcers or 
injured corneal tissues. The ability of EGF to decrease gastric acid secretion and to stimulate the 
proliferation of mucosa cells can explain its gastroprotective role and its efficiency in healing of 
ulcers, making it a promising new line of therapy for gastroduodenal ulcers. 
 
Role of EGF pathway in organogenesis 
Investigation of tissues from midterm human fetuses has proved that immunoreactive 
EGF is found at almost the same sites as in the adult and has brought light on the time of 
appearance of EGF in tissues. Placenta, the distal tubules of kidney, the surface epithelium of 
stomach and the skin of the fetus are the early sites for the immunohistochemical localization of 
EGF (as early as week 15). The tips of villi, the exocrine glands of the gastrointestinal tract, the 
proximal and collecting tubules of the kidney and the glands of trachea are the next to present 
EGF, from weeks 16-17 of gestation[138]. 
In human lungs, however, throughout the gestational period the expression of EGF 
appears to follow a developmental pattern: in the early stage of lung development (weeks 7 to 26 
of gestation), when the formation of preacinar airways, the extension and branching of the 
respiratory bronchioles and invasion of capillaries into the lung take place, EGF is highly 
expressed in the proximal airways (trachea and bronchi). Later on, during the saccular and 
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alveolar stages of lung development when alveolar units are formed, EGF seems to be mainly 
localized to alveolar type II cells and to alveolar macrophages[61;150]. This information comes in 
agreement with studies that have evidenced the role EGF has in promoting the maturation of 
distal airways in rabbits[22] and lambs[177] and in the acceleration of alveolar type II proliferation 
in vitro as well as in vivo[61;135]. 
Moreover, extensive studies on human lungs have shown that from week 11 of 
gestational age until 1 year of age EGF and its receptors colocalize and they are consistently 
present in the bronchial epithelium and submucosal glands, bronchiolar and alveolar epithelium 
as well as in vascular smooth muscle cells[118;175]. Intraalveolar macrophages were also 
consistently immunostained for EGF and EGF receptor[169;175]. Furthermore, 
immunohistochemical assays performed in human adults confirmed the distribution observed in 
fetuses, determining that EGF is found mainly in bronchial epithelial cells and, to a lesser extent, 
in trachea[87]. Also, the fact that EGF serum concentrations change with age, the highest 
concentration being seen up to 9 years of age[133] suggests that EGF continues to play a role in 
the process of cell proliferation even in the postnatal period.  
 
I.3.2. Pathologic involvement of the EGF pathway 
 
The upregulation of the EGF pathway has been shown to be involved in the pathogenesis 
of many types of malignancies, contributing to their development by stimulating proliferation 
and inhibiting apoptosis, by inducing angiogenesis and promoting tumor cells motility, adhesion 
and metastasis[4;68].  
a. The overexpression of EGF receptors is one of the incriminating factors in the 
development of human tumors like breast, head and neck, gastric, colorectal, prostate, ovarian or 
non-small cell lung cancers, being associated with a high metastatic rate, a poor tumor 
differentiation, resistance to standard therapy, an increased risk of disease recurrence and poor 
patient prognosis[9;13;192].  
EGF receptor type I overexpression can be caused by an increased EGFR gene 
transcription or by EGFR gene amplification and cells presenting a pattern of EGFR 
overexpression have more aggressive growth and invasiveness characteristics[199]. Studies 
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performed on more than 20.000 patients have identified the high levels of EGFR expression as 
having a strong prognostic value for head and neck carcinoma, ovarian, bladder, cervical and 
esophageal cancers, a moderate prognostic value for breast, gastric and endometrial tumors and 
a weak prognostic value for non-small cell lung cancers[119]. 
The overexpression of HER2 (mostly due to gene amplification) has been evidenced in 
several types of neoplasias like breast, ovarian, stomach, pancreatic, colon carcinomas or non 
small cell lung cancers[156] and it has been shown that it can be an important factor in the 
oncogenic transformation of normal tissues especially from the mammary gland[63]. HER2 
overexpression, especially coexpressed with HER1 and/or HER3, was associated with a very 
high invasive potential and reduced survival in breast cancer patients[106;123;146] and in some 
studies, to resistance to anti-estrogen therapy[15].  
b. The degree of activation of the EGF receptors is, however, as important for 
carcinogenesis as the level of receptor expression. Factors affecting the activation status 
(increased levels of receptor ligands, EGFR mutations or heterodimerization of EGFR with other 
members of this receptor family –for example with HER2) can also lead to increased EGFR 
signaling.  
Mutations of EGF receptors: The loss of 267 aminoacids from the EGFR extracellular 
domain due to the deletion of exons 2 to 7 of the wild-type EGFR gene is the most common 
mutation of this receptor (also known as EGFRvIII, del 2-7 EGFR or ∆EGFR), rendering the 
resulted form of the receptor not downregulable by endocytosis and thus constitutively 
active[122]. Less frequent mutations like deletions of aminoacids 746-750 or aminoacid 
substitution have also been described[128] and their presence has been detected not only in 
malignant cells[162] but also in the normal epithelium of respiratory structures surrounding the 
tumor, identifying these molecular perturbations as an early event of carcinogenesis, at least in 
the lung[178]. It has been recently shown that mutations in the kinase domain of EGFR in 
particular render a better response to TK-inhibitors[100;128], whereas mutations in the 
extracellular could not be correlated with a response to TK inhibitors[13].  
Heterodimerization of EGF receptors:  In contrast with the homodimeric forms of 
EGFR, which signal weakly because they are subjected to receptor downregulation and 
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degradation after ligand mediated activation[167], heterodimers of EGFR and HER2 are more 
stable due to their increased affinity for the ligands and ability to be recycled[198]. This explains 
the poorer survival and higher treatment failure rates in patients with coexpression of EGFR and 
HER2[16]. Coexpression of EGFR, ErbB2 and ErbB3 also has a negative synergistic effect on 
patients outcome, independently of the tumor size and lymph node status[197], being often 
associated with a more aggressive phenotype and a worse prognosis[123].  
 
The involvement of EGF pathway in the development of neoplasias can be explained by 
the important anti-apoptotic and pro-angiogenic effects it has on cells. EGFR can prevent 
apoptosis by upregulating the expression of apoptosis inhibitory proteins like c-FLIP capable of 
inhibiting caspase-8 function[10] or by upregulating the anti-apoptotic molecules of the Bcl-2 
family (Bcl-2, Bcl-XL, Mcl-1)[67;96]. Also, EGF and the activated EGFR can enhance the process 
of angiogenesis through the upregulation of VEGF[48;142]. 
 
I.3.3. EGF receptors inhibitors 
The large amount of data regarding the involvement of EGF signaling pathway in the 
development and progression of neoplasias has raised the interest on designing and testing 
EGFR inhibitors that could block signaling at different levels of this pathway. Gefitinib 
(Iressa®), erlotinib (Tarceva®) and lapatinib (Tykerb®) are antagonists that inhibit the 
intracellular normal function of the EGFRs tyrosine-kinases by competing with ATP for its 
binding site on the intracellular domain of EGFR. They have already proven antiproliferative 
effects both in experimental settings and clinical trials and are currently being used in the 
clinical practice as first or second line therapies. 
Gefitinib (Iressa®, originally coded ZD1839, AstraZeneca), an anilinoquinazoline 
(chemical formula: 4-Quinazolinamine N-(3-chloro-4-fluorophenyl)-7-methyl-6-[3-4-
morpholynpropoxy]) (Figure 5) available for oral administration, is a reversible and highly 
specific inhibitor of EGFR tyrosine-kinase. Gefitinib can be administered both intravenously 
and orally; after oral administration it is moderately slow absorbed (mean bioavailability of 
59%), and peak plasma concentrations are reached after 3-7 hours.  After 90% binding to plasma 
proteins (serum albumin and alpha-1 acid glycoprotein), gefitinib is extensively distributed into 
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tissues and mainly metabolized by CYP3A4. Having a mean half-life of 41 hours, gefitinib 
achieves a steady state after 7-10 days, with a 2 to 8 fold accumulation after once daily 
administration[76]. 
Due to its effect of tumor shrinkage and stabilization, improvement of symptoms as well 
as to its very good tolerability[53], it has been approved for clinical administration as 
monotherapy in patients with locally advanced or metastatic non small cells lung cancer 
(NSCLC) after failure of chemotherapy in more than 30 countries worldwide. However, because 
it failed to improve survival rates in patients with NSCLC included in a large double-blind, 
placebo-controlled randomized trial[164], gefitinib use has been restricted only to those patients 
that have already benefited from it (especially Asian patients, females, non-smokers and patients 
with adenocarcinomas), which account for approximately 10% of patients with 
NSCLC[53;95;180]. Due to the fact that it is a selective drug, gefitinib has a superior safety and 
tolerability profile in comparison with cytotoxic agents; the most common side effects are 
anorexia, asthenia, nausea, vomiting, mild to moderate diarrhoea, dehydration, skin rash and 
asymptomatic elevations of liver enzymes. However, although rare (<1% of patients), several 
severe adverse effects were described after treatment with Iressa: corneal erosion, aberrant 
eyelash growth, interstitial lung disease (with fatal cases), pancreatitis and hepatitis, 
myelosuppression and Stevens Johnson syndrome. 
In patients in which gefitinib has not proven its efficacy, Erlotinib (OSI-774, Tarceva®, 
Roche), another low-molecular-weight, specific and reversible EGFR tyrosine-kinase specific 
inhibitor has been administered, with better results. Due to its synergistic and additive effects 
when associated with chemotherapy agents or radiotherapy and to the survival benefit it has 
proved in the treatment of lung cancer in phase III trials, erlotinib is currently being used as 
monotherapy in patients with locally advanced or metastatic NSCLC that have not benefited 
from gefitinib or chemotherapy and, since 2005, as first line therapy for locally advanced, 
unresectable or metastatic pancreatic cancer in combination with gemcitabine[43;45]. Several 
serious adverse effects have been described after the use of erlotinib, including gastrointestinal 
perforations (with very high mortality), liver function impairment (elevated transaminases and 
bilirubin), corneal ulcerations or perforations, keratitis, conjunctivitis, skin and subcutaneous 
tissue disorders (hair and nail changes, bullous, blistering or exfoliative skin disorders, Stevens-
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Johnson syndrome). Also, an excess of myocardial infarction/ischaemia and cerebrovascular 
accidents was observed in the group of patients treated with both Tarceva and gemcitabine in 
comparison with patients treated with gemcitabine alone[179]. 
Erlotinib is a quinazolinamine (N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-
quinazolinamine) (Figure 5) that is well absorbed after oral therapy (bioavailability of 59%) and 
reaches peak plasma levels at approximately 4 hours after administration. Following absorbtion, 
it is highly bound in blood, especially to albumin and alpha-1 acid glycoprotein, metabolized 
mainly by the hepatic cytochromes CYP3A4/CYP3A5 (80-95%) and eliminated as metabolites 
mainly via the faeces (>90%). With a half-life of 36.2 hours, erlotinib administered daily at a 
dose of 150 mg reaches a steady state plasma concentration in approximately 7-8 days[179]. 
 
 
Figure 5. Chemical structures of gefitinib (ZD1839) and erlotinib (OSI-774) 
 
 
Lapatinib (GW572016, Tykerb®, GlaxoSmithKline) is a low molecular weight, 
reversible, dual EGFR/HER2 tyrosine kinase inhibitor, which also belongs to the 4-
anilinoquinazoline class of kinase inhibitors (chemical formula: N-(3chloro-4-{[(3-
fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-
quinazolinamine bis(4 methylbenzenesulfonate) monohydrate) (Figure 6). Following oral 
administration, lapatinib is incompletly absorbed and peak plasma concentrations are achieved 
after 4 hours from administration. Lapatinib is highly bound (>99%) to albumin and alpha-1 
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acid glycoprotein, metabolized mainly by CYP3A4 and CYP3A5 (with a half-life of 14.2 hours) 
and daily treatment allows the achievement of a steady state in approximately 6-7 days[188].  
Lapatinib has been used since the moment of its approval by FDA in 2007, in association 
with capecitabine for the treatment of women with refractory advanced and metastatic breast 
cancer overexpressing HER2[50] who had progressive disease after treatment with trastuzumab 
(Herceptin) or other cancer therapies[18]. It is currently investigated as monotherapy or in 
combination with other regimens. Results from 44 clinical trials indicated an overall favourable 
toxicity profile of lapatinib with a low frequency of events that are usually reversible[185].  
However, treatment with lapatinib was associated in some patients with the decrease of left 
ventricular ejection fraction, QT prolongation as well as with interstitial lung disease or 
pneumonitis, palmar-plantar erythrodysesthesia, severe diarrhea and hepatotoxicity, which 
underline the necessity of increased monitorisation of patients with already impared cardiac, 
pulmonary or hepatic function. 
 
 
 Figure 6. Chemical structure of lapatinib (GW572016) 
 
 
I.4. Aim of the study 
 
Using rats in which PH was induced by administrating a single dose of MCT, the present 
study aimed to: 
1. investigate the therapeutic efficacy of continuous chronic EGF signaling pathway inhibition 
2. evaluate the therapeutic efficacy of three different EGF receptor inhibitors (gefitinib, 
erlotinib, lapatinib) in delaying the progression of the disease in a head-to head experiment. 
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II.A. MATERIALS 
 
II.A.1. Animal experiments 
 
Adult male Sprague- Dawley rats, weighing 300 to 350 g were obtained from Charles 
River and Harlan Winkelman Laboratories. Animals were housed under controled temperature 
(approximatelly 22º C) and food and water were provided ad libitum. All experiments were 
performed according to the international guidelines regarding animal experiments. 
 
II.A.2. Substances and reagents 
 
SUBSTANCE  
(CHEMICAL NAME) 
SUBSTANCE  
(COMMERCIAL NAME OR KIT)
DISTRIBUTION  
COMPANY 
 
A. Induction of pulmonary hypertension in Sprague-Dawley rats  
 
Monocrotaline Crotaline ®  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
Sodium hydroxide 1N (1 mol/l)  Merck, Darmstadt, Germany 
Chlorhidric acid 1 N (1 mol/l)  Merck, Darmstadt, Germany 
Enrofloxacine Baytril 2.5 % ® Bayer Vital GmbH, Leverkusen, 
Germany 
Isoflurane  Baxter Deutschland GmbH, 
Unterschleiβheim, Germany 
Methylcellulose  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
 
B. Catheterization of the right heart and tissue processing 
 
Ventilation gas (50% O2, 50% N2)  Air Liquid (ehem.Messer), Siegen, 
Germany 
Povidone-iodine solution Braunoderm ®  B.Braun Melsungen AG, Melsungen, 
Germany 
Ketaminhydrochloride 100 mg/ml Ketavet ®  Pharmacia GmbH,Berlin,Germany 
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Medetomidinhydrochloride 1mg/ml Domitor ®  Pfizer GmbH, Berlin,Germany 
Heparine Heparin-Natrium-25.000-
ratiopharm®  
Ratiopharm GmbH,Ulm, Germany 
Physiological saline solution (NaCl 
0.9%) 
 B.Braun Melsungen AG, Melsungen, 
Germany 
Distilled water  B.Braun Melsungen AG, Melsungen, 
Germany 
Aprotinin Trasylol ®  Bayer Vital GmbH, Leverkusen, 
Germany 
Pentoxifylline 20 mg/ml Trental ®  Sanofi Aventis, Frankfurt am Main, 
Germany 
Formaline Formaldehyd-Lősung 3.5-3.7% Otto Fischar GmbH&Co.KG, 
Saarbrücken, Germany 
 
C. Histology  
 
Paraffin embedding medium Paraplast Plus ® Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
Sodium chloride  Carl Roth GmbH&Co, Karlsruhe, 
Germany 
Potassium chloride  Carl Roth GmbH&Co, Karlsruhe, 
Germany 
Dinatriumhydrogenphosphat dihydrat 
(Na2HPO4·2H20) 
 Merck, Darmstadt, Germany 
Kaliumdihydrogenphosphat (KH2PO4)  Merck, Darmstadt, Germany 
Roti-Histol (Xylol) Roti®- Histol  Carl Roth GmbH, Karlsruhe, 
Germany 
Ethanol 70%, 96%, 99.6%  Otto Fischar GmbH&Co.KG, 
Saarbrücken, Germany 
Isopropylalkohol (99.8%)  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
Mounting medium Pertex ® Medite GmbH, Burgdorf, Germany  
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Specific reagents for medial wall thickness assessment 
 
Resorcin-Fuchsin  Waldeck GmbH&Co.KG, Münster, 
Germany 
Nuclear-Fast Red- Alum. Sulpha Kernechtrot Aluminiumsulfat Waldeck GmbH&Co.KG, Münster, 
Germany 
 
 
Specific reagents for muscularization degree assessment 
 
Methanol  Sigma Aldrich Chemie GmbH, 
Steinheim, Germany 
Hydrogen peroxide 30%  Merck, Darmstadt, Germany 
Trypsin Digest All 2 ® Invitrogen Corporation, Camarillo, 
CA,USA 
Normal Horse Serum  Alexis Biochemicals, Grünberg, 
Germany 
Streptavidin-Biotin-Blocking Kit  Linaris Biologische Produkte GmbH, 
Wertheim-Bettingen, Germany 
Vectastain ABC Kit   Linaris Biologische Produkte GmbH, 
Wertheim-Bettingen, Germany 
Horseradish peroxidase streptavidin RTU Horseradish peroxidase 
streptavidin 
Vector Laboratories, Burlingame, 
CA,USA 
Vector VIP Vector® VIP substrate kit for 
peroxidase (SK-4600) 
Vector Laboratories, Burlingame, 
CA,USA 
DAB Substrat Kit  DAB Substrate Kit for peroxidase 
(SK-4100) 
Vector Laboratories, Burlingame, 
CA,USA 
Methylgreen Methyl Green (H-3402) Vector Laboratories, Burlingame, 
CA,USA 
 
Specific reagents for proliferation degree assessment 
 
Citrate Buffer   Zymed Laboratories Inc., Invitrogen, 
Carlsbad, USA 
Methanol  Sigma Aldrich Chemie GmbH, 
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Steinheim, Germany 
Hydrogen peroxide 30%  Merck, Darmstadt, Germany 
Proteinase K Dako Real ™, Proteinase K (40x) Dako Denmark A/S, Glostrup, Denmark
Proteinase K diluent Dako Real ™ Proteinase K 
diluent  
Dako Denmark A/S, Glostrup, Denmark
Peroxidase ImmPress™ Reagent Kit  Linaris Biologische Produkte GmbH, 
Wertheim-Bettingen, Germany 
Nova RED Substrate Kit Vector ® Nova RED ™ Substrate 
Kit for peroxidase 
Linaris Biologische Produkte GmbH, 
Wertheim-Bettingen, Germany 
Hematoxylin Hematoxylin QS (H-3404) Vector Laboratories, Burlingame, 
CA,USA 
 
Antibodies 
 
Anti- alpha smooth muscle actin antibody 
(Monoclonal, mouse anti-human) 
Clone 1A4 Sigma  Sigma Aldrich, Steinheim, Germany 
Anti- von Willebrand factor antibody  
(Polyclonal, rabbit anti-human) 
 Dako Cytomation, Hamburg, Germany 
Anti –PCNA antibody (Rabbit polyclonal 
IgG)  
PCNA antibody (FL-261): sc-
7907    
Santa Cruz Biotechnology, Santa Cruz, 
CA, USA 
 
 
II.A.3. Consumables  
 
PRODUCT 
 
PRODUCT  
(COMMERCIAL NAME OR KIT)
DISTRIBUTION  
COMPANY 
 
A. Induction of pulmonary hypertension in rats, chronic treatment and catheterization of 
the right heart 
 
Single use gloves Nitra-Tex® Ansell Ltd, Tamworth, Staffordshire, 
UK 
Napkins  Tork, Mannheim, Germany 
Needles: 18G (1.2 mm x 40 mm), 20G 
(0.9 mm x 40 mm), 26G (0.45mm x 
BD Microlance 3® Becton Dickinson GmbH, Heidelberg, 
Germany 
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13mm) 
Single use syringes 1ml, 2 ml, 5 ml, 20 
ml 
Injekt®- F  B.Braun Melsungen AG, Melsungen, 
Germany 
Black thread no.16   Coats GmbH, Kenzingen, Germany 
Medical adhesive bands 2.5 cm/ 9.2 m 3M™ Durapore™ Surgical Tape 3M Health Care, St.Paul, MN, USA 
Gauze 4x5 cm Purzellin ® Lohmann und Rauscher, Rengsdorf, 
Germany 
Gauze balls size 6, unsteril  Fuhrmann Verrbandstoffe GmbH, 
Munich, Germany 
Surgical instruments  Fine Science Tools GmbH, 
Heidelberg, Germany  
Martin Medizintechnik, Tuttlingen, 
Germany 
Cannula for vein catheter support 22G  Vasocan Braunüle ® B.Braun Melsungen AG, Melsungen, 
Germany 
Instrument for venous catheter insertion Intradyn ™ Venous Hemostasis 
Introducer 
B.Braun Melsungen AG, Melsungen, 
Germany 
Silicone catheter for right heart 
catheterization 
 Custom-made 
Polyethylene cannula for insertion into 
the carotid artery 
Vasofix ® Safety ®, 22G B.Braun Melsungen AG, Melsungen, 
Germany 
Tracheal cannula  Custom-made from BD Microlance 3® 
15 or 20G  needles (Becton Dickinson, 
Germany) shortened to 1.5 cm 
Stopcock for infusion therapy and 
pressure monitoring 
Discofix ® C-3 B.Braun Melsungen AG, Melsungen, 
Germany 
Rat restrainer (model 81)  IITC Life Science Inc., 
Woodland Hills, CA, USA 
Heating underlay ThermoLux®  Witte + Sutor GmbH, Murrhardt, 
Germany 
Eppendorf tubes (Microtubes 1.5 ml)  Sarstedt, Nürnbrecht, Germany 
Scalpels Feather Disposable Scalpel  Feather Safety Razor Co, LTD, Osaka, 
Japan 
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B. Histology 
 
Histological glass slides 25x75x1 mm SuperFrost UltraPlus® R. Langenbrinck, Emmendingen, 
Germany 
Embedding cassettes  Leica Microsystems, Nussloch, 
Germany 
Coverslips 24x 36 mm  Menzel GmbH&Co.KG, 
Braunschweig, Germany 
Microtom blades Microtome blade type A35  Feather Safety Razor Co Ltd, Osaka, 
Japan 
Tips for automatic pipettes 200 µl, 1000 
µl, 10 µl 
 Sarstedt, Nürnbrecht, Germany 
Automatic pipettes 10-100 µl, 1-10 µl Eppendorf PhysioCare concept Eppendorf AG, Hamburg, Germany 
 
 
II.A.4. Systems and machines  
 
PRODUCT 
 
PRODUCT  
(COMMERCIAL NAME) 
DISTRIBUTION  
COMPANY 
 
A. Induction of pulmonary hypertension in rats, chronic treatment and catheterization of 
the right heart 
 
Weighing machine for animals Sauter RP 3000 August Sauter GmbH, Albstadt- 
Ebingen, Bayer Leverkusen  
Balance for substances Mettler Toledo PB303 Delta 
Range®  
Mettler Toledo, Switzerland 
Transducers Combitrans Monitoring Set Mod.II 
for Arterial Blood Pressure 
Management 
B.Braun Melsungen AG, Melsungen, 
Germany 
Ventilation system for rats SAR- 830/P Ventilator IITH Life Science Inc., Woodland 
Hills, CA, USA  
Computer and screen   
Blood analyzer Rapidlab™ 348 Bayer Healthcare, Fernwald, 
Germany 
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Centrifuge Hettich Mikro 200R Hettich-Zentrifugen GmbH & Co. KG, 
Tuttlingen, Germany 
 
 
B. Histology 
 
Tissue dehydrating machine Leica TP 1050 Leica Microsystems, Nussloch 
GmbH, Germany 
Tissue embedding machine Leica EG 1140 H Leica Microsystems, Nussloch 
GmbH, Germany 
Cooling table Leica EG 1150 C Leica Microsystems, Nussloch 
GmbH, Germany 
Automated microtom Leica RM 2165 Leica Microsystems, Nussloch 
GmbH, Germany 
Flattening table Leica HI 1220 Leica Microsystems, Nussloch 
GmbH, Germany 
Flattening bath for paraffin sections Leica HI 1210 Leica Microsystems, Nussloch 
GmbH, Germany 
Computer  Q 550 IW Leica Microsystems, Nussloch 
GmbH, Germany 
Software Q Win V3 Leica Microsystems, Nussloch 
GmbH, Germany 
Light microscope DMLA  Leica Microsystems, Nussloch 
GmbH, Germany 
Ice flake machine Icematic F100 Compact Castelmac SPA, Castelfranco, Italy 
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II.B. METHODS 
 
II.B.1. Animal experiments: Monocrotaline-induced pulmonary hypertension 
 
Pulmonary hypertension was induced in adult male Sprague-Dawley rats of 300 to 350 
grams in bodyweight (Charles River Laboratories) via subcutaneous administration of 
monocrotaline (60 mg/kg). Monocrotaline solution was freshly prepared, by dissolving the 
alkaloid in 1N HCl and 1N NaOH (250 mg alkaloid dissolved in 3 ml 1N HCl and 2 ml 1N 
NaOH and pH adjusted to 7.4). A single injection of monocrotaline was administered on day 0, 
after light anesthesia with Isoflurane®. Control rats received 500 µl saline solution 
subcutaneously under the same conditions. In order to avoid opportunistic infections, rats were 
administered an antibiotic solution (Baytril® 2.5%) from day 1 to 15 in the drinking water, at a 
concentration of 2 ml Baytril/ 500 ml water.  
 
 
II.B.2. Therapy with EGFR inhibitors 
 
Three weeks after the administration of the monocrotaline solution, rats were subjected 
to daily oral treatment with EGF receptor inhibitors gefitinib (Iressa), erlotinib (Tarceva) and 
lapatinib (Tykerb). The tablets were crushed and dissolved in 1.5% methylcellulose solution, 
previously prepared and stored at 4º C. Fresh solutions of the three inhibitors were used at every 
administration and the necessary volume of solution was calculated every day for each animal 
according to the rat body weight. Treatment was administered under light anesthesia with 
Isoflurane® using a rat gavage feeding needle, once per day, from day 21 to 35. The animals 
were divided into several groups, in order to test two different doses for each inhibitor: 30 and 
10 mg/kg bodyweight for gefitinib, 10 and 5 mg/kg bodyweight for erlotinib and lapatinib, 
respectively (Figure 7). Considering the lack of published articles regarding the efficient range 
of doses of the investigated EGFR inhibitors in experimental pulmonary hypertension, the doses 
of gefitinib, erlotinib and lapatinib were selected based on our pilot experiments regarding 
toxicity and tolerability and on previously published studies in rats with different 
pathologies[51;64;86;159].  
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The placebo (MCT 35 days) group received daily 1 ml 1.5% methylcellulose, under the 
same conditions (orally, once per day, from day 21 to 35).  
 
Figure 7. Experimental plan for chronic administration of EGFR inhibitors gefitinib, erlotinib and lapatinib 
II.B.3. Catheterization of the right heart 
 
In order to monitor hemodynamic changes, rats were subjected to right heart 
catheterization 21 and 35 days after the administration of monocrotaline. Rats were initially 
anesthetized by intraperitoneal injection with Ketamine/Domitor solution 10:1 (1 µl Ketamine/1 
g bodyweight) and placed on a heating pad for maintainance of body temperature in a 
physiological range. Animals were tracheotomized and artificially ventilated with a mixture of 
oxygen and nitrogen (1:1), at a constant frequence of 60 breaths per minute, with an inspiratory 
flow rate of 500 to 600 cc/min. The inspiratory time was 0.5 seconds and the positive end 
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expiratory pressure (PEEP) was set to 1 cmH2O. The left carotid artery was isolated and 
cannulated with a polyethylene cannula connected to a fluid-filled force transducer and the 
systemic arterial pressure (SAP) was measured throughout the surgical procedure. The right 
jugular vein was also isolated and cannulated and the right heart was catheterized through the 
jugular vein, using a home-made silicone catheter connected to a fluid-filled force transducer. 
The catheter was advanced into the right ventricle under the guidance of pressure tracing. A 
volume of 1 ml heparin solution (10%, dissolved in saline solution) was administered through 
the jugular vein, in order to prevent blood coagulation. Using fluid force transducers (calibrated 
at zero to the hillum level before the beginning of the procedure) and the Labtech Pro (Labtech 
Notebook Runtime Version 9.02) computer software, records of ventilation pressure, arterial 
systemic pressure (SAP) and right ventricular systolic pressure (RVSP) were taken for 5 to 10 
minutes. Immediately after catheterization, 300 to 400 µl arterial and venous blood samples 
were prelevated and analyzed for oxygenation and CO2 levels, arterial and venous pH, 
haemoglobin and hematocrit levels, using the Rapid lab™ 348 blood analyzer.  
Arterial blood samples were also collected for plasma separation using a mixture (1:2) of 
the anticoagulant pentoxifylline (Trental®) and proteinase inhibitor aprotinin (Trasylol®); blood 
was centrifuged at room temperature for 10 minutes at 12500 RPM. The supernatant was 
collected and immediately snap frozen in liquid nitrogen and further used for molecular biology 
analysis. Cardiac output and index (CI) values were calculated for each rat based on Fick’s 
formula (see Table 2), using haemoglobin, arterial and venous saturation values obtained from 
the blood samples prelevated at the beginning of the surgery. Pulmonary and systemic vascular 
resistance indexes (TPR, TSR) were calculated based on right ventricular systolic and systemic 
arterial pressures measured during the surgery and the cardiac index values obtained as 
described.  
 
Table 2. Formulas for calculation of cardiac output (CO), cardiac index (CI), total pulmonary vascular 
resistance index (TPR) and total systemic vascular resistance index (TSR) 
CO (ml/min) = 5.46/ ((Hb*arterial saturation*0.0134) – (Hb*venous saturation*0.0134)) 
CI (ml/min*100 g BW) = Cardiac output/ Bodyweight 
TPR (mmHg* 100 gBW *min / ml) = RVSP / CI                          
TSR (mmHg* 100 gBW *min / ml) = SAP / CI 
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II.B.4. Tissue processing 
 
The abdomen and thoracic cavity were opened and the left and the right ventricles were 
incised in order to allow the removal of blood (the right ventricle was incised at 5 mm below the 
base of pulmonary artery). A cannula connected to a reservoir filled with saline solution was 
inserted into the pulmonary artery through the right ventricle and the lungs were flushed out of 
blood at a pressure of 30 cmH2O above the pulmonary hillum. The right hilum was then 
tightened with a thin thread, allowing the removal of the right lung which was immediately snap 
frozen in liquid nitrogen. Plasma and the right lung were then preserved at (-80)º C. The left 
lung was prepared for histology using a cannula inserted into the pulmonary artery, connected to 
a reservoir filled with 3.5-3.7% formalin solution. The left lung was perfused at a pressure of 30 
cmH2O above the pulmonary hillum for 5 to 10 minutes, further isolated and stored in 3.5-3.7% 
formalin solution at 4º C over night and then in phosphate buffer (pH=7.4) until dehydration and 
histological analysis. The heart was prelevated and the right ventricular wall (RV) was separated 
from the block of left ventricular wall (LV) plus ventricular septum (S). The samples were dried 
for 48 hours at room temperature, the dry weights were measured and heart ratio (as an index of 
right heart hypertrophy) was calculated as RV/ (LV+S).  
 
 
II.B.5. Histological analysis – medial wall thickness and assessment of the degree of  
muscularization  
 
After the prelevation of the left lung as described above, sections of aproximately 4 mm 
in width were obtained and placed in histological cassettes, dehydrated in an automatic 
dehydration machine and then embedded in paraffin. Sections of 3 µm in diameter were cut from 
the paraffin blocks using a Leica microtome (Leica RM 2165), were maintained at 37˚C for 24 
hours and then used for staining.  
For the assessment of the muscularization degree of small peripheral pulmonary arteries, 
the sections were maintained for 20 minutes at 60˚C, deparaffinized in xylol and progressively 
rehydrated.  Endogenous peroxidase was blocked by treating the sections for 20 minutes at room 
temperature (RT) with a freshly prepared solution of 30% hydrogen peroxide in methanol (1:1) 
and unspecific background staining due to endogenous streptavidin and biotin was eliminated by 
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consecutively overlaying the slides with streptavidin blocking solution for 15 minutes (followed 
by 5 minutes wash in PBS) and biotin blocking solution for 15 minutes at RT (followed by 5 
minutes wash in PBS). For the staining of vascular smooth muscle and endothelium, the slides 
were initially incubated with normal horse serum for 30 minutes (to eliminate non-specific 
binding caused by immunoglobulin cross-reactivity) and then incubated with a mouse anti α-
smooth muscle cells actin primary antibody (at RT) and a rabbit anti-von Willebrand factor 
primary antibody respectively (at 37° C); both antibodies were diluted 1:900 in 10% BSA and 
maintained for 30 minutes. Slides were further washed for 4 times (5 minutes each) in PBS and 
immediately incubated with the corresponding biotinylated anti-mouse and anti-rabbit secondary 
antibodies, for 30 minutes at RT. Specific substrates were used for the induction of a colour 
reaction by horseradish peroxidase streptavidin coupled to the secondary antibodies: VIP 
substrate (maintained for 1.5 minutes at RT) determined the purple/violet colour of the smooth 
muscle layer and DAB (maintained for 30 seconds at RT) determined the brown colour of the 
endothelium. Methylgreen (5 minutes, at 60° C) was used as counterstaining for nuclei and 
slides were then progressively dehydrated, mounted with Pertex mounting medium and left to 
dry over night.  
The sections were subsequently analyzed by light microscopy using a software that 
distinguishes between the purple and brown colour of the structures and categorizes the vessels 
into nonmuscularized (smooth muscle covering less than 5% of the vessel wall area), partially 
muscularized (5 to 75% smooth muscle around the vessel) and fully muscularized (75 to 100% 
muscle around the vessel). 80 to 100 vessels of 20-50 µm in diameter in each lung were 
analyzed at 40x magnification, and the percentage of vessels in each muscularization category 
was calculated by dividing the number of vessels in that category to the total number of vessels 
counted for each particular lung. 
 
For wall thickness assessment the sections were incubated at 58-60° C for 20 minutes, 
deparaffinized in xylol and progressivly rehydrated in graded alcohols. For staining the elastic 
fibers the slides were maintaned in Resorcin-Fuchsin over night (16 hours on average) at RT 
(which determined the blueish-black colour of elastic fibers) and after two times washing with 
distilled water, Nuclear Fast Red was used as a red nuclear counterstaining for 10 minutes at RT. 
Excess of dyes was removed by two times immersion in distilled water and progressively 
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increased ethanol concentrations were used for dehydration of slides before their mount with 
Pertex mounting medium. 
80-100 intraacinar arteries were analyzed at 40x magnification for every lung; the 
distance between lamina elastica interna and lamina elastica externa was automatically 
calculated for every vessel by the Qwin (Leica) software as an average of at least 3 
measurements. Arteries were categorized according to their external diameter, as follows: 
category I included vessels with an external diameter of 20 to 50 µm; category II included 
vessels with an external diameter of 51 to 90 µm, category III included vessels with an external 
diameter of 91 to 150 µm whereas vessels with an external diameter of more than 151 µm were 
considered category IV vessels. Medial wall thickness was automatically calculated as 
percentage, using the formula:  
 
                     % MWT= (2*wall thickness/external diameter) *100.  
 
 
II.B.6. Histological analysis – Assessment of the level of proliferation 
 
In order to assess proliferation in the pulmonary vessel walls from rats injected with 
MCT and treated with EGF receptor inhibitors, tissue sections were incubated at 58-60° C, 
deparaffinized in xylol and rehydrated using ethanols with decreasing concentration degrees and 
distilled water. In order to enhance the antigen retrieval process, the slides were incubated with 
citrate buffer (pH=6; diluted 1:20 in distilled water) in water bath for 20 minutes, allowed to 
cool in the buffer for 30 minutes at RT and then washed with distilled water for 5 minutes. The 
slides were further incubated with a solution of hydrogen peroxide 30% in methanol (1:1) for 20 
minutes in order to block endogenous peroxidases and washed in distilled water and PBS (two 
times 5 minutes each). Further on, they were treated with proteinase K (a second antigen 
retrieval solution) for 15 minutes at RT, washed in distilled water and PBS (3 times, for 5 
minutes each) and incubated in 10% BSA for one hour. 
For the specific staining of proliferating cell nuclear antigen, the slides were pretreated 
with normal horse serum for 20 minutes (to block non-specific bindings of the antibody to the 
tissue) and then incubated overnight at 4° C (in order to allow a better penetration of the 
antibody into the paraffin sections) with a primary rabbit anti-PCNA antibody (diluted 1:100 in 
10% BSA). The excess of primary antibody was removed by washing the slides with PBS every 
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20 minutes for 2h. Peroxide-conjugated anti-rabbit IgGs were used as secondary antibody. In 
order to visualize the proliferating nuclei, the slides were further treated with NovaRED 
substrate for 5 minutes at RT (which determined the red/brown colour) and the colour reaction 
was terminated by immersing the slides in tap water for 5 minutes. Hematoxylin QS (30-40 
seconds) was used for nuclear counterstaining. The excess of dye was removed by consecutive 
washing with tap water, PBS buffer and distilled water. The slides were prepared for final 
mounting with Pertex by progressive dehydration. 
The Qwin (Leica) software was used to select vessels with an external diameter of 20 to 
50 µm and positive and negative cells from 40 to 80 vessels in each lung were counted. The 
index of in situ proliferation was calculated using the formula:  
 
IOP (%)=Number of PCNA-positive cells in the vessel/ Number of all cells in the vessel 
 
and all variations in the treatment groups were calculated using as reference value (considered 
100%) the mean value of IOP from healthy rats. 
 
 
II.B.7. Bodyweight changes and distress score assessment 
  
Rats from all groups were weighed and monitored and the average bodyweight and 
distress score were calculated every day from day 21 to 35. In order to determine the gain/loss of 
weight, the average bodyweight on day 22 was considered as reference value for comparison 
with the average bodyweight values of every day. Average relative weight change was 
calculated as percentage of change in weight at day 35 compared with the weight at the 
beginning of treatment.  
During treatment animals were also given a grade from 0 to 4 for several parameters 
(appearance, bodyweight changes, clinical signs, natural and provoked behaviour) and the total 
score per day was calculated as a sum of all grades given for the analyzed parameters (see Table 
3). A total score of 0 to 4 was considered to indicate a normal animal, a score between 5 and 9 
was considered to indicate a suffering animal and possible use of analgesics, whereas a score 
higher than 10 indicated a severely sick animal, in which termination should be taken into 
account. Average relative distress score change was calculated as percentage of change in 
distress score at day 35 compared with the distress score at the beginning of treatment.  
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Table 3. Distress scoring assessment 
 
Animal identification Score 
Appearance Normal 0 
 General lack of grooming, dull, yellowing coat 1 
 Coat staring, ocular/nasal discharge 2 
 Pinched features, dehydrated, pale eyes 3 
Bodyweight changes Normal (stagnation is already a sign of illness) 1 
 Bodyweight loss <5% 2 
 Bodyweight loss 5-10% 3 
 Bodyweight loss 10-15% 4 
Clinical signs Normal respiratory rate and pattern 0 
 Slight changes, increased rate 1 
 Dyspnea, tachypnes with abdominal breathing 2 
 Marked abdominal breathing with cyanosis 3 
Natural behaviour Normal 0 
 Minor changes 1 
 Less alert 2 
 Isolation or very still 3 
Provoked behaviour Normal 0 
 Minor depression or exaggerated response 1 
 Moderate change 2 
 Reacts on handling violently/vocalisation or very still 3 
 
 
 
II.B.8. Data analysis 
Data are given as means ± standard error mean (SEM). Statistical comparisons were 
made using one-way ANOVA followed by a Student Newman Keuls post-hoc test. A value of 
P< 0.05 was considered to be statistically significant. 
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EGF receptor inhibition as treatment of experimental PAH 
 
III.1. Effects of EGFR inhibition on hemodynamic parameters in monocrotaline rats  
 
Right ventricular systolic pressure (RVSP) was significantly elevated after 21 days from 
the administration of MCT (39.7 ± 5.4 mmHg compared with 25.5 ± 1.1 mmHg in healthy rats) 
and further increased until day 35 (73.6 ± 1.5 mmHg). Chronic treatment with the EGFR 
inhibitors from day 21 to 35 resulted in a significant decrease of RVSP. Administration of all 
three EGFR antagonists reduced RVSP in a dose-dependent manner and gefitinib proved to be 
the most effective in delaying the progression of the disease (Figure 8), by reducing RVSP to 
levels comparable to those seen in the MCT 21 days group (Table 4), at both doses used (41.7 ± 
3.8 mmHg and 42.1 ± 4.1 mmHg for gefitinib 30 and 10 mg/kg, respectively). Erlotinib and 
lapatinib also significantly reduced RVSP in comparison with the placebo rats, displaying 
comparable effects at the same dose (47.7 ± 4.5 mmHg for erlotinib 10 mg/kg versus 49.5 ± 5.1 
mmHg for lapatinib 10 mg/kg and 54 ± 5.0 mmHg for erlotinib 5 mg/kg versus 52.7 ± 6.8 
mmHg for lapatinib 5 mg/kg) (Figure 8). A tendency towards decrease of the systemic arterial 
pressure was noticed 35 days after the injection of monocrotaline, although it was not significant 
(Figure 9).  
 
 
 
Figure 8. Effects of EGFR inhibitors (gefitinib, erlotinib and lapatinib) on right ventricular 
systolic pressure in MCT-injected rats. Rats were randomly divided in two treatment groups for each 
inhibitor and drugs were administered daily, by oral gavage, from day 21 to 35 after the injection of MCT. 
Two doses were used for every inhibitor (30 and 10 mg/kg for gefitinib, 10 and 5 mg/kg for erlotinib and 
lapatinib, respectively). An invasive technique for measuring hemodynamic parameters was used for 
assessing right ventricular systolic pressure (RVSP) (n=10-15). Each bar represents mean ± SEM. * P<0.05 
vs control; † P<0.05 vs. MCT at day 35.  
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No significant changes in the cardiac index (CI) were noted in the monocrotaline group 
(26.9 ± 2.9 ml/min*100 g BW in MCT 35 days animals compared to 30.9 ± 1.9 ml/min*100 g 
BW in healthy rats). Furthermore, no significant changes could be noticed in any of the 
experimental groups (Figure 10).  
The assessment of the oxygenation level showed that thirty five days after MCT 
administration, arterial oxygenation was significantly decreased (351 ± 38.3 mmHg, in 
comparison with 506 ± 14.6 mmHg healthy rats) (Figure 11). However, the values of arterial 
oxygenation in all treated groups were comparable to those observed in placebo rats, showing no 
significant difference. The doses of the EGFR inhibitors used were selected based on previous 
publications and on our pilot experiments addressing long-term tolerability (data not shown). 
Figure 9. Effects of EGFR inhibitors (gefitinib, erlotinib and lapatinib) on systemic arterial 
pressure in MCT-injected rats. Rats injected with MCT and treated with EGFR inhibitors gefitinib (30 
and 10 mg/kg), erlotinib (10 and 5 mg/kg) and lapatinib (10 and 5 mg/kg) from day 21 to 35 after 
monocrotaline injection were subjected to invasive techiques for the measurement of hemodynamic 
parameters and systemic arterial pressure (SAP) was assessed (n=10-15). Each bar represents mean ± SEM. 
* P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
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Figure 11. Effect of EGFR inhibition on gas exchange in rats with MCT-induced pulmonary 
hypertension. Arterial blood samples prelevated during the surgery after right heart catheterization were 
immediately analyzed and arterial oxygenation index (PaO2/FiO2) (in mmHg) was determined (n=10-
15). Each bar represents mean ± SEM. * P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
Figure 10. Effect of EGFR inhibition on cardiac index in rats with MCT-induced pulmonary 
hypertension. Treatment with two doses for each inhibitor tested (30 and 10 mg/kg for gefitinib, 10 and 5 
mg/kg for erlotinib and lapatinib, respectively) was administered daily, by oral gavage, from day 21 to 35. 
Cardiac index was assessed based on Fick’s formula and hemodynamic parameters measured during the 
surgery (n=10-15). Each bar represents mean ± SEM. * P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
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The total pulmonary vascular resistance index (TPR) was significantly increased in 
MCT-injected rats receiving placebo (2.2 ± 0.1 versus 0.7 ± 0.1 mmHg min/ml 100g BW in 
healthy rats). Corroborating the RVSP data there was significant decrease in TPR of gefitinib 
(1.4 ± 0.1 and 1.3 ± 0.1 mmHg min/ml 100g BW respectively for high and low dose) and high 
dose erlotinib groups (1.5 ± 0.1 mmHg min/ml 100g BW) (Figure 12). However, low dose 
erlotinib and high as well as low dose lapatinib treatment did not result in a significant reduction 
of TPR (1.7 ± 0.2, 1.7 ± 0.1 and 1.8 ± 0.1 mmHg min/ml 100g BW respectively).  
Also, no significant change among the experimental groups was assessed regarding the 
systemic vascular resistance index (TSR) (Figure 13).  
 
 
 
 
 
 
 
 
 
Figure 12. Effect of EGFR inhibition on total pulmonary vascular resistance index in rats with 
MCT-induced pulmonary hypertension. Rats were treated from day 21 to 35 after MCT injection 
with EGFR inhibitors. Gefitinib (10 and 30 mg/kg bodyweight), erlotinib (5 and 10 mg/kg) and lapatinib 
(5 and 10 mg/kg) were administered daily by gavage and hemodynamic measurement was performed at 
the end of treatment. An equal volume of the vehicle methylcellulose was given to the placebo group. 
Total pulmonary vascular resistance index (TPR) is given (n=10-15). Each bar represents mean ± SEM.  
* P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
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III.2. Effects of EGFR inhibitors on right heart hypertrophy in monocrotaline rats 
 
The increase in RVSP observed after the administration of MCT was paralleled by a 
progressive development of right heart hypertrophy assessed by the RV/(LV+S) ratio. Right 
heart hypertrophy was significantly increased 21 days (0.32 ± 0.02) and 35 days after the 
administration of MCT (0.6 ± 0.03 versus 0.25 ± 0.01 in healthy rats) (Figure 14, Table 5). The 
RV/BW ratio (in mg/g) showed the same progressive trend following MCT administration (0.12 
± 0.06 in healthy, 0.18 ± 0.01 in MCT 21 days and 0.3 ± 0.02 in MCT 35 days rats, respectively) 
(Tables 4, 5). Chronic treatment with gefitinib, erlotinib or lapatinib reduced right heart 
hypertrophy in a dose-dependent way, gefitinib at both doses demonstrating the most potent 
effect in this respect (0.37 ± 0.04 and 0.38 ± 0.02 in the case of gefitinib 30 and 10 mg/kg, 
respectively). A significant effect could be assessed only in the case of the group treated with the 
Figure 13. Effect of EGFR inhibition on total systemic resistance index in rats with MCT-induced 
pulmonary hypertension. Rats were treated with gefitinib (10 and 30 mg/kg bodyweight), erlotinib (5 and 
10 mg/kg) and lapatinib (5 and 10 mg/kg) from day 21 to 35 after MCT injection, followed by invasive 
hemodynamic measurements. Total systemic resistance index (TSR) was evaluated based on hemodynamic 
parameters determined during the surgery (n=10-15). Each bar represents mean ± SEM. 
* P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
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highest dose of erlotinib (0.43 ± 0.01) and no significant reduction of heart ratio could be seen 
after using lapatinib at both dose regimens (0.5 ± 0.07 and 0.52 ± 0.06 for lapatinib 10 and 5 
mg/kg respectively) or erlotinib at the lowest dose (0.48 ± 0.04). The RV/BW ratio also 
demonstrated a significant reduction of right heart hypertrophy in all treated groups and a 
tendency towards dose-dependency was noticed (Table 4).  
On the other hand, the progressive development of right heart hypertrophy during the 
course of the disease was not paralleled by a similar increase of (LV+S)/BW ratio (considered as 
a marker of left heart hypertrophy) in any of the experimental groups we investigated (Table 4). 
 
Table 4. RV/BW and (LV+S)/BW ratios in healthy, MCT 35 days and treated rats (n=10-15)  
 
 RV / BW (mg/g) (LV+S) / BW (mg/g) 
Healthy 0.12 ± 0.06  0.47 ± 0.01  
MCT 35 days 0.3 ± 0.02 (*) 0.51 ± 0.02 
Gefitinib 30 mg/kg 0.18 ± 0.01 (†) 0.49 ± 0.01 
Gefitinib 10 mg/kg 0.22 ± 0.02 (†) 0.56 ± 0.04 
Erlotinib 10 mg/kg 0.2 ± 0.01 (†) 0.49 ± 0.02 
Erlotinib 5 mg/kg 0.23 ± 0.02 (†) 0.5 ± 0.02 
Lapatinib 10 mg/kg 0.22 ± 0.03 (†) 0.46 ± 0.01 
Lapatinib 5 mg/kg 0.22 ± 0.02 (†) 0.44 ± 0.01  
 
*  P<0.05 versus healthy control; † P<0.05 versus MCT 35 days  
Figure 14. Effect of EGFR inhibition on 
right heart hypertrophy in rats with MCT-
induced pulmonary hypertension. Animals 
were exposed to MCT and then treated daily, by 
oral gavage, from day 21 to 35, with two doses 
for each inhibitor (30 and 10 mg/kg for gefitinib, 
10 and 5 mg/kg for erlotinib and lapatinib, 
respectively). Right to left ventricular plus 
septum weight ratio (RV/LV+S) of the treated 
versus placebo groups are given (n=10). Each 
bar represents mean ± SEM. * P<0.05 vs control; 
† P<0.05 vs. MCT at day 35.  
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III.3. Effects of EGFR inhibitors on pulmonary vascular remodeling in monocrotaline rats 
 
We investigated medial wall thickness and the degree of muscularization of small 
peripheral pulmonary arteries (25 to 50 µm in diameter) as markers of pulmonary vascular 
remodeling. Injection of MCT resulted in an enhanced pulmonary artery muscularization as 
evident from the enhanced immunoreactivity for α-SMC actin (Figure 15). Morphometric 
analysis revealed significantly increased fully muscularized vessels at day 21 (Table 5) and 
further at day 35 (59 ± 6.1 %) as compared to healthy control animals (2.8 ± 1.1 %) (Figure 16). 
Similarly, chronic treatment with high and low dose gefitinib and high dose erlotinib 
significantly reduced the number of fully muscularized vessels (10 ± 3.4 %, 22.5 ± 8.6 % and 
17.1 ± 4.2 %, respectively) as compared to the placebo group, whereas the reduction was not 
significant in the low dose erlotinib (44.4 ± 8.6 %) and both dose groups of lapatinib  
(38 ± 7.6 % and 35.5 ± 10.0 %) (Figure 16). The increase in fully muscularized vessels was 
accompanied by a significant decrease of non-muscularized vessels in the placebo group (22.3 ± 
5.1 % at day 35) compared to the healthy control (67.7 ± 5.3 %). The non-muscularized vessels 
in rats treated with high and low dose gefitinib (67.9 ± 6.5 % and 56.6 ± 10.3%) and high dose 
erlotinib (62.6 ± 8.2 %) were comparable to healthy control. However, a reduced number of 
non-muscularized vessels was noted in both doses of lapatinib (36.8 ± 9.1 % and 37.8 ± 7.3 %) 
and low dose erlotinib (30.8 ± 9.9 %) treated groups and it was comparable to that of the 
placebo group (Figure 16).  
 
 
 
Figure 15. Effect of treatment with EGFR inhibitors on the degree of muscularization of small 
pulmonary arteries of MCT-injected rats. The rat lung sections were immunostained for von 
Willebrand factor (brown) and α-smooth muscle actin (purple). Representative pictures of experimental 
groups are shown: (A) healthy control, (B) placebo, (C) gefitinib, (D) erlotinib, (E) lapatinib. Pulmonary 
vascular morphometry was performed on the double immunostained lung sections. A total of 80 to 100 
intraacinar vessels were analyzed in each lung. Scale bar: 20 µm. 
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Analysis of the medial wall thickness revealed a significant increase at day 35 (21.1 ± 
0.3 %) as compared to healthy control (13.0 ± 0.1 %) (Figures 17, 18). Chronic treatment with 
the EGFR inhibitors resulted in a significantly reduced medial wall thickness in all investigated 
groups. Gefitinib (15.1 ± 0.1 and 16.4 ± 0.2 %) and high dose erlotinib (15.9 ± 0.2 %) exhibited 
Figure 16. Effect of treatment with gefitinib, erlotinib and lapatinib on the degree of 
muscularization of small pulmonary arteries of MCT-injected rats. The rat lung sections were 
immunostained for von Willebrand factor (brown) and α-smooth muscle actin (purple). Pulmonary 
vascular morphometry was performed on the double immunostained lung sections. A total of 80 to 100 
intraacinar vessels were analyzed in each lung. The degree of muscularization was assessed as percentage 
of muscle area from the total pulmonary artery cross section (25-50 µm). The proportion of 
nonmuscularized (N), partially muscularized (P) or fully muscularized pulmonary arteries (F) is given. 
Results from MCT-injected rats as well as treated groups and healthy control rats are presented.  Rats were 
treated as described in methods (n=8-12). Each bar represents mean ± SEM.  
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the strongest effect, reducing this parameter to values comparable to MCT 21 days rats (Table 
5), whereas the effect was milder in the groups treated with low dose erlotinib (18.0 ± 0.3 %) 
and lapatinib at both doses (17.8 ± 0.2 and 19.2 ± 0.3 %) (Figure 18).  
 
 
 
 
 
 
 
 
Figure 17. Effect of treatment with EGFR inhibitors on medial wall thickness of small pulmonary 
arteries of MCT-injected rats. Treatment with gefitinib, erlotinib and lapatinib was administered orally, 
daily, and two doses were used for every tested drug. The rat lung sections were stained with elastica staining 
for wall thickness determination. Representative pictures of experimental groups are shown: (A) healthy 
control, (B) placebo, (C) gefitinib, (D) erlotinib, (E) lapatinib. Scale bar: 20 µm. 
Figure 18. Effect of treatment with gefitinib, erlotinib and lapatinib on medial wall thickness of 
small pulmonary arteries of MCT-injected rats. Treatment with gefitinib, erlotinib and lapatinib was 
administered orally, daily, and two doses were used for every tested drug. The rat lung sections were further 
stained with elastica staining for wall thickness determination. A total of 80 to 100 intraacinar vessels were 
analyzed in each lung. The medial wall thickness (%) is shown. Results from MCT-injected rats as well as 
treated groups and healthy control rats are presented (n=8-12). E ch bar represents mean ± SEM.  
* P<0.05 vs control; † P<0.05 vs. MCT at day 35. 
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Table 5. RVSP, SAP, RV/(LV+S), RV/BW, (LV+S)/BW, degree of muscularization and medial wall 
thickness of healthy and monocrotaline-injected rats (day 21) (n=10). 
 
 Healthy MCT 21 days 
RVSP (mmHg) 24.5 ± 1.3 38.4 ±3.4 (*) 
SAP (mmHg) 74.3 ± 4.8  66.4 ± 3.9 
RV/(LV+S) 0.26 ± 0.01 0.32 ± 0.02 (*) 
RV/BW (mg/g) 0.12 ± 0.01  0.18 ± 0.01 
(LV+S)/BW (mg/g) 0.47 ± 0.01 0.53 ± 0.04 
Degree of Non 67.7 ± 5.3 39.3 ± 8.4 (*) 
muscularization Partial 29.6 ± 4.8 37.1 ± 4.5 
(%) Full 2.8 ± 1.1 23.5 ± 7.0 (*) 
Medial wall thickness (%) 13.0 ± 0.14 16.4 ± 0.17 (*) 
 
*  p< 0.05 versus healthy control 
 
 
III.4. Effects of EGFR inhibitors on proliferation levels in monocrotaline rats 
 
Following the injection of MCT, we observed an enhanced immunoreactivity for PCNA 
due to an increased number of proliferating cells within the walls of small pulmonary arteries 
(Figure 20). The index of in situ proliferation was significantly higher 21 days after the 
administration of MCT (more than 6 fold versus healthy controls) and further increased until 35 
days (more than 8 times than in healthy rats) (Figure 19). Treatment with all EGFR antagonists 
reduced the index of proliferation to lower levels than those seen in the MCT 21 days rats. 
Although not statistically significant, the efficacy of all three used drugs was similar when the 
highest dose was employed for each of them, with gefitinib demonstrating a slightly higher 
efficacy in inhibiting this parameter (Figure 19). 
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Figure 20. Effect of treatment with EGFR inhibitors on proliferation within small pulmonary 
arteries walls. Treatment with gefitinib, erlotinib and lapatinib was administered orally, daily, and two doses 
were used for every tested drug. The rat lung sections were stained for proliferating cells. Representative 
pictures of experimental groups are shown: (A) healthy control, (B) placebo, (C) gefitinib, (D) erlotinib, (E) 
lapatinib. Scale bar: 50 µm. 
Figure 19. Effect of treatment with gefitinib, erlotinib and lapatinib on proliferation levels within 
small pulmonary arteries walls. The rat lung sections were stained for proliferating cell nuclear antigen 
(PCNA) (red-brown). Positive and negative cells from 40 to 80 vessels in each lung were counted and the 
index of in situ proliferation (A) was calculated as percentage of PCNA-positive cells in the vessel from all 
cells in the vessel. Results from MCT-injected rats as well as treated groups and healthy control rats are 
presented.  Rats were treated as described in methods (n=5). Each bar represents mean ± SEM.  
* P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
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III.5. Effects of EGFR inhibitors on body weight changes and distress score in 
monocrotaline rats 
 
As compared to healthy animals, placebo rats lost weight during the 2-weeks surveillance 
period (Figure 21). In contrast, rats treated with gefitinib and erlotinib at both doses had 
increased bodyweights at day 35 as compared to the weights measured at the beginning of the 
therapy. Gefitinib demonstrated a similar effect at both doses (more than 2% increase) whereas 
erlotinib at the lowest dose had a better effect (2.46%) than the higher dose (0.86%). In the 
lapatinib treated rats we observed that at the end of the 35 days surveillance period animals had 
no increase in their body weight in comparison with the moment when therapy was initiated and 
lapatinib rats treated with the highest dose had a worse outcome (0.34% weight loss). Also, an 
abrupt descending trend was noticed in both lapatinib treated groups during the first week of 
treatment, followed by a gradual recovery during the second week of treatment. 
 
 
 
 
Figure 21. Effect of treatment with gefitinib, erlotinib and lapatinib on body weight. Healthy, 
placebo as well as treated rats were monitored and body weight changes were recorded daily from the onset 
of treatment to the end (n=10). Average relative bodyweight change during the surveillance period was 
calculated as percentage in weight at day 35 compared with the weight at the beginning of treatment.  
Each bar represents mean ± SEM. * P<0.05 vs control; † P<0.05 vs. MCT at day 35.  
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Furthermore, several physical parameters as general appearance, respiratory pattern, 
natural and provoked behaviour were used to calculate a distress score. Placebo challenged rats 
had a worsening health state with obvious changes in the respiratory pattern (from increased 
respiratory rate to marked abdominal breathing with cyanosis), the general appearance 
(dehydration, yellowing coat, nasal discharge) and natural behaviour (isolation, lack of 
alertness), which resulted in a high distress score at the end of day 35 (Figure 22). Gefitinib was 
well tolerated as shown by the low distress score in this group, comparable to that seen in 
healthy rats, and by the complete lack of development of pathological respiratory signs. 
Similarly, erlotinib treated rats had a low distress score at the end of day 35 (comparable to that 
assessed in the gefitinib group) but overt signs of respiratory disease were observed during the 
treatment period (dyspnea or abdominal breathing). Lapatinib-treated rats, on the other hand, 
showed no significant improvement of their condition during treatment, presenting frequent 
pathological changes of the respiratory pattern, side effects like facial edema and diarrhea as 
well as a high distress score at the end of day 35. 
 
Figure 22. Effect of treatment with 
gefitinib, erlotinib and lapatinib on the 
overall state of health. Control and treated 
rats were monitored daily and a distress score 
assessing a set of physical parameters, 
including respiratory changes, was calculated 
(n=10). Each bar represents mean ± SEM. * 
P<0.05 vs control; † P<0.05 vs. MCT at day 
35.  
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Gefitinib also proved to be the best tolerated drug, inducing no mortality in the treated rats, 
as compared to erlotinib, which was associated with a mortality of 8% during treatment and the 
placebo-challenged MCT injected rats (20%) (Figure 23). Lapatinib treated rats, on the other 
hand, had the highest mortality rate among the treatment groups, with 87% survival at the end of 
day 35. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 23. Effect of treatment with gefitinib, 
erlotinib and lapatinib on mortality rate. 
Healthy, placebo and treated rats were monitored 
daily from week 3 to 5 after MCT injection (n=10-
18). Survival rate was calculated as the percentage 
of surviving animals relative to the alive animals 
on day 21, the first day of treatment. Survival rates 
of all experimental groups are shown. Each point 
on the graph represents the day after 
monocrotaline injection. 
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The pathological mechanisms of PAH are now known to be closely correlated with the 
involvement of several factors having vasoactive or mitogenic properties, among which the 
family of growth factors seems to play a significant role. Various growth factors like 
PDGF[74;158] or VEGF[26;154] have lately emerged as important players in the development of the 
disease and others like EGF[107], insulin-like growth factor-1 (IGF-1)[5;38] or basic fibroblast 
growth factor (bFGF)[193] also seem to be involved in the development of the remodeling 
process taking place in the hypertensive lung. They act as potent mitogens and chemoattractants 
for smooth muscle cells, fibroblasts and endothelial cells, which results in increased cell 
proliferation, resistance to apoptosis or migration of pulmonary vascular cells and finally in the 
establishment of overt pulmonary disease. The progress made in the understanding of PAH 
pathogenesis has also opened new paths for the therapeutic approach of this condition and novel 
compounds like endothelin receptor antagonists, nonparenteral prostanoids, phosphodiesterase 5 
inhibitors, activators of soluble guanilate cyclase or tyrosine kinase inhibitors have been 
suggested to be promising new agents in the PAH field[127]. However, search for novel targets 
and more effective anti-remodeling therapy have remained highly desirable. 
Recently, several original publications have demonstrated that Imatinib, by inhibiting 
PDGF signaling, can reverse experimental PAH in two independent models[158]. These 
preclinical results have later been translated into the clinic and the first case reports of patients 
with PAH treated with Imatinib have demonstrated improved hemodynamics and 6-minute walk 
distance[57;131;168]. Imatinib was designed to target the ATP-binding site of RTKs and has been 
approved for therapy against chronic myelogenous leukemia and malignant gastrointestinal 
stromal tumors, thus providing an example of transferred knowledge from cancer treatment. 
Furthermore, recent studies have demonstrated that PKI166, an EGFR inhibitor, could mediate 
VSMC apoptosis and improve the survival of MCT-injected rats[107].  
 
IV. 1. EGF signaling  in pulmonary hypertension 
Recent experiments performed on animal models of PAH (mice overexpressing TGFα 
and MCT-treated rats) have demonstrated the involvement of the EGF pathway in the 
pathogenesis of experimental PAH. Le Cras et al. [97] were able to induce the hemodynamic and 
histologic characteristics of severe pulmonary vascular disease by overexpressing TGFα in mice. 
DISCUSSION 
___________________________________________________________________________________ 
 
 
New  Therapeutic Strategies for the Treatment of Experimental Pulmonary Hypertension:  
Role of the Epidermal Growth Factor 
 
58
The induced expression of a mutated form of EGFR in the same type of transgenic mice 
prevented the development of the disease and improved the main parameters that are 
pathologically affected during the course of the disease.  
The hypothesis of the involvement of EGFR signaling pathway in the pathogenesis of 
pulmonary arterial hypertension through the stimulation of pulmonary vascular SMC was 
supported by experiments performed in rats with baloon-injured carotid artery. In these rats the 
application of a blocking EGFR antibody before and after the injury led to the attenuation of 
intimal hyperplasia and to the decrease of SMC proliferation in arterial vessels[24]. Also, in vitro 
experiments performed on cultured vascular SMCs prelevated from pulmonary hypertensive 
fawn-hooded rats or human pulmonary arteries demonstrated an increased proliferation in 
response to the EGF exposure[79;85;160]. The hypoxic stimulus has an additive effect, by inducing 
increases in EGFR expression[7]. It also enhances the mitogenic effects of growth factors like 
bFGF, EGF and PDGF through the induction of nuclear HIF-1α expression and the stimulation 
of the DNA synthesis in PASMC[101;160].  
In human PAH, however, direct evidences are scarce. The involvement of the EGF 
pathway in the development of the disease was mainly demonstrated by the histologic 
assessment of increased expression of EGF in the medial, adventitial and neointimal layers of 
pulmonary arteries, which accompanied the progression of the pulmonary vascular disease in 
children[83]. Recently, however, experiments performed by our group, investigating the 
pulmonary expression of HERs and their ligands in patients with IPAH[37] have revealed no 
significant alteration of the ligands (betacellulin, amphiregulin and HB-EGF) or of their 
receptors (HER 1-4) in the lung tissue from these patients. Also, no significant up-regulation of 
the HER1 protein was observed, suggesting altogether that the EGF signaling pathway may not 
be an indispensable player at least in the late stage of the disease progression. However, as the 
lung tissues obtained from patients undergoing lung transplantation may have end-stage 
pathological alterations, a possibility for EGF signaling contributing to the early disease 
progression could not be entirely ruled out.  
Several factors have been shown to interact with the EGF pathway and converge towards 
VSMC and fibroblast proliferation, endothelial thickening and ultimately PAH development. 
The EGF-induced proliferation and migration of SMCs is critically dependent on tenascin-C 
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(TN-C), as has been shown by the necessity of exogenous TN-C addition on type I collagen gels 
when EGF-dependent SMC proliferation was attempted. In contrast, other growth factors-
induced SMC proliferation (e.g. bFGF) takes place even in the absence of TN-C[85]. TN-C is a 
component of the extracellular matrix involved in tissue remodeling[85], which promotes the 
accumulation of EGF receptors in clusters and the redistribution of the actin cytoskeleton at the 
cell periphery[84]. The interaction with the EGFR signaling pathway is due to its binding to the 
αvβ3 integrins, which form with growth factor receptor signaling components a specialized focal 
adhesion complex on the actin-based cytoskeletal scaffold[108;136]. Thus, the promotion of the 
clustering and phoshorylation of receptor tyrosine kinases including the ones of EGF receptors 
takes place (Figure 27). The interaction between the αvβ3 integrins and TN-C is also essential for 
the EGF-dependent SMC proliferation, as demonstrated by the inhibitory effect of an anti-αvβ3 
integrin monoclonal antibody on SMC growth in response to EGF[84].  
 
Figure 24. Proposed mechanism of interaction between tenascin-C (TN-C), endothelin (ET)  and the EGF 
pathway (adapted after Iwasaki H. et al., 1998[78]) (Gq=phospholipase C- coupled Gq protein, ET-A= endothelin 
receptor type A). The black arrows symbolize the induction of intracellular signaling pathways. 
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The induction of TN-C transcription in pulmonary hypertension has been previously 
linked to the increased activity of elastase[102;200], which can induce the activation of matrix 
metalloproteinases. Consequently, the degradation of the extracellular matrix, the release of 
growth factors in active form and the transcription of TN-C take place, which can trigger the 
activation of the EGF pathway[107]. Moreover, angiotensin II, an important mediator of VSMCs 
growth, has been shown to induce, via reactive oxygen species (ROS) like H2O2, the 
phosphorylation of the EGF receptor[191]. Furthermore, the transactivation of EGFR has been 
connected to the process of thrombin and endothelin signaling leading to SMC migration[78;88] 
(Figure 27).  
 
 IV.2. EGF receptor inhibition in experimental PAH  
Results obtained in Sprague-Dawley rats with MCT-induced pulmonary vascular disease 
confirmed the participation of the EGF pathway in the pathogenesis of PH through the 
prevention of the development of the disease with EGFR-tyrosine kinase inhibitors. One of the 
inhibitors used- AG1478, a thyrophostin described in 1989 as a potent and selective EGFR-TK 
inhibitor, was able to induce, via prevention of EGFR phosphorylation, growth arrest and 
apoptosis in PASMC cell culture and organ cultures of hypertrophied rat pulmonary 
arteries[107;116]. Also, PKI166, another EGFR inhibitor, could reduce PAP, right heart 
hypertrophy, medial wall thickness and the degree of muscularization of small pulmonary 
arteries. Also, it increased the survival rate of MCT challenged rats when administered daily or 
three times a week and the maintainance of positive results could be assessed even 4 weeks after 
the cessation of therapy[107]. However, despite the remarkable potency exhibited in animal 
models and the fact that it is a dual EGFR/HER2 inhibitor, PKI166 failed to pass the early 
phases of clinical trials[141], which presently renders it not a viable therapeutic alternative in 
human PAH.  
On the other hand, clinically approved EGFR inhibitors, like gefitinib (Iressa®), 
erlotinib (Tarceva®) and lapatinib (Tykerb®), which have already demonstrated their efficacy in 
human patients with NSCLC[30;32], pancreatic[45] and breast cancer[152] are available. Moreover, 
unlike other RTK antagonists (Sunitinib) or monoclonal antibodies against HER2 
(Trastuzumab), which have been described to possess cardiotoxicity[27;103], the above mentioned 
DISCUSSION 
___________________________________________________________________________________ 
 
 
New  Therapeutic Strategies for the Treatment of Experimental Pulmonary Hypertension:  
Role of the Epidermal Growth Factor 
 
61
drugs have been recently included in the category of low cardiotoxicity receptor TK 
inhibitors[49]. Also, these EGFR antagonists are orally active (unlike agents as Trastuzumab, 
which require intravenous administration and can induce allergic reactions), are associated in 
most cases with mild adverse effects (mostly cutaneous rash and diarrhea) and do not induce the 
typical cytotoxic reactions affecting patients treated with chemotherapy[28]. These characteristics 
make them an attractive alternative to current available therapies. These findings provided us 
with a good rationale to further investigate the potential therapeutic application of clinically 
approved EGFR inhibitors in PAH. 
Considering the previous evidence suggesting an EGFR signaling-mediated development 
of PAH as well as the availability of cancer-effective EGFR targeted therapy, the aims of the 
present study were to 1). evaluate the efficacy of chronic EGF receptor inhibition on the 
progression of MCT-induced PAH and 2). to investigate and compare the in vivo effects of three 
different clinically available EGF receptor inhibitors, in particular gefitinib, erlotinib and 
lapatinib, in a head-to-head experiment. We therefore used a well–established animal model of 
PAH (the MCT model) and focused on the study of hemodynamic and pulmonary vascular 
remodeling-related parameters as well as on the consequences of the above mentioned EGFR 
antagonists on the general health status and mortality rate. Our results demonstrate 1). a partial 
and dose-dependent efficacy of EGFR antagonists in improving the hemodynamic and histologic 
parameters associated with the disease, with gefitinib having the most prominent effect at both 
doses used. We also show 2). a superior tolerability profile of gefitinib over the other two tested 
inhibitors regarding the impact of therapy on the organism as a whole, as reflected by the 
bodyweight changes, lower distress score and survival advantage.  
PAH is a progressive disease caused by the thickening of precapillary arteries, which 
leads to a gradual increase in pulmonary vascular resistance, pulmonary arterial pressure, right 
ventricle afterload and finally right heart failure[74]. In rats a single injection of the pyrazollidine 
alkaloid MCT induces, after 21 days, a significant increase of RVSP, right heart hypertrophy 
and degree of muscularization[143;147], which further progress within the next weeks. In this 
context, we investigated the effect of chronic daily EGFR inhibition on the progression of the 
disease in a well established animal model of PAH.  
The results of our experiments demonstrated that daily administration of EGFR TK 
inhibitors in MCT rats for two weeks starting at day 22 (when the disease is completely 
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established) led to a reduction of pulmonary arterial pressure in all experimental groups, 
regardless of the used dosage and showed a tendency towards dose-dependency in the case of all 
three EGFR inhibitors. Considering the lack of detectable vasodilatory effect of any of the 
investigated inhibitors, as reflected by SAP and TSR, the significant effect on pulmonary arterial 
pressure is most likely the consequence of the anti-remodeling effect of the drugs employed in 
this study on pulmonary arteries. This conclusion is supported by our data showing the 
significant and potent effect these inhibitors have in reducing the proliferation level within the 
vessel walls, medial wall thickness and the neomuscularization process, which is considered to 
be one of the main factor involved in the development of the disease. The reduction of 
muscularization resulted in a consistent delay in pulmonary vascular resistance (TPR) increase 
and, as a consequence, in pulmonary arterial pressure, which was prominent in the case of 
gefitinib at both doses and in the high-dose erlotinib group. Our results are not entirely 
surprising considering the already proven effects gefitinib, erlotinib and lapatinib have on 
cellular proliferation, as they are drugs with antiproliferative, apoptosis-inducive effects in 
different cancer cell lines and mice with xenografted human tumors[72;151;165]. In addition, the 
cardiac index was comparable among the experimental groups, suggesting that the cardiac 
output was not affected by the treatment and that the EGFR inhibitors do not have cardiac-
specific toxicity at least at the doses and duration tested in our study. This is in line with the 
recent report categorizing these EGFR inhibitors as receptor tyrosine kinase inhibitors with low 
cardiotoxicity[49]. Furthermore, right heart hypertrophy, which is a constant finding during the 
course of pulmonary hypertension both in the MCT model and human patients[25;173] was 
significantly reduced in comparison with placebo-treated rats, as demonstrated by parameters 
like RV/(LV+S) ratio and right ventricle to bodyweight ratio (RV/BW). Both of these 
parameters have been shown to progressively increase after MCT administration[82;158]. Our data 
confirm the previously mentioned results published by Merklinger et al.[107] showing the potent 
in vivo effect of daily administration of the antiproliferative and selective EGFR/HER2 inhibitor 
PKI166. Used under similar conditions to those employed in our study, PKI166 was able to 
improve the hemodynamic and histologic parameters associated with pulmonary hypertension, 
including right heart hypertrophy. 
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Treatment of animals with MCT leads not only to the development of pulmonary 
hypertension, but also to a progressive deterioration of the overall physical health status, as 
assessed by the significant decrease of body weight[82] and a high mortality rate[35;184]. Also, 
pathological changes in the general appearance, behaviour[46] and respiratory pattern[17;147] have 
been described during the course of the disease. Furthermore, human patients with severe heart 
failure often present with significant weight loss leading to cachexia, due to anorexia, nausea 
and vomiting, to the impairment of intestinal absorption or to the increased work performed by 
the respiratory muscles[65]. Furthermore, cardiac failure is often associated with a poorer quality 
of life, closely correlated with the NYHA functional class[70;144] and with a high mortality rate, 
especially in the first months after diagnosis[36]. In this context, we were further interested to 
study the effect of these three EGFR inhibitors not only in relation with the pulmonary vascular 
changes but also on the overall health status of MCT injected rats, with emphasis on bodyweight 
changes and the distress level.  
The majority of the studies investigating the consequence of gefitinib and erlotinib as 
monotherapy or in combination with other drugs on bodyweight changes failed to show any 
significant change of the net bodyweight and only a few reported a reduction of animals 
bodyweight at the end of the treatment[105]. In contrast, we could observe a physical 
improvement, as shown by the tendency of increase in weight in both gefitinib groups and in the 
lower dose erlotinib group. On the other hand, administration of erlotinib at the highest dose 
used as well as lapatinib at both doses had as a consequence an initial decrease of bodyweight, 
especially in the first week of treatment, which was followed by a gradual recovery. The 
negative impact of lapatinib on animals bodyweight suggests, in correlation with a high distress 
score, the high toxicity level of this drug and comes in agreement with studies performed in 
animal models[44;111]. The decrease in bodyweight was also a frequently described adverse 
effect in human patients treated for cancer with this drug[114]. Moreover, the presence of 
respiratory pathological signs and the higher mortality rate in the lapatinib treated animals in 
comparison with gefitinib and erlotinib treated rats point out a rather negative outcome in this 
group and support the conclusion that, among the EGFR inhibitors we tested, lapatinib has the 
worst tolerability profile. Gefitinib, on the other hand, due to the 100% survival rate and distress 
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score values comparable to healthy levels, was the best tolerated drug when used at the dose of 
30 mg/kg.  
The molecular analysis performed in our group[37] on whole lungs prelevated from MCT 
challenged rats detected an upregulation of the transcripts for EGF and TGFα, the ligands for 
EGFR1, as well as a significant upregulation of ErbB1, ErbB2 and ErbB3 but not of ErbB4 
transcripts in the lungs from MCT-injected rats as compared with healthy rats. Surprisingly 
however, the EGFR1 protein level was comparable to that found in the healthy rat lungs. This 
observation is in agreement with Northcott and colleagues, who found a 4.2-fold increase in 
mRNA but no difference in the EGFR protein in aorta from deoxycorticosterone acetate-salt 
hypertensive rats as compared with that from normotensive sham rats[124]. Despite the absence 
of significant upregulation of EGFR proteins in the MCT model, treatment with gefitinib and 
erlotinib resulted in beneficial effects, which come in support to the in vitro experiments 
performed in our group[37]. Gefitinib, erlotinib and lapatinib significantly inhibited the EGF-
induced proliferation of primary rat PASMCs with comparable efficacy. In contrast, despite its 
dual EGFR/ErbB2 inhibitory effect and potent in vitro effect, lapatinib did not succeed in 
providing a therapeutic benefit of significantly attenuating the right heart hypertrophy and 
pulmonary vascular remodeling in the MCT model. Although surprising, the lack of efficacy of 
lapatinib is however not uncommon, as previous studies in the cancer field have shown that 
lapatinib activity is not dependent on the EGFR expression level in HER2-overexpressing breast 
cancer cells and that its clinical efficacy is limited only to the treatment of ErbB2 overexpressing 
breast cancer[88;112;201].  
The therapeutic efficacy of gefitinib and erlotinib may be attributable to their inhibition 
of EGFR-induced pulmonary vascular SMC proliferation as also observed in vitro in cell culture 
studies performed in our group, and may be explained by the enhanced EGFR signaling, which 
is possible through mechanisms such as different combinations of receptor dimerization[195] or 
the crosstalk with other receptor types[88;130;153;182]. Also, although it is classically considered a 
specific inhibitor of EGFR1, for which it has a 100-fold greater selectivity over other tyrosine 
kinases in the cell[64], the remarkable efficacy of gefitinib in the MCT model can also be the 
consequence of its inhibitory activity on numerous other intracellular transmembrane tyrosine 
kinases[31] (see Figure 28). Indeed, our findings, which are suggestive of the discrepancy in the 
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efficacy of the EGFR antagonists in inhibiting PASMC proliferation in vitro and in vivo may be 
attributable to the presence of other growth factors that are involved in the complex in vivo 
environment and can also play an independent role in the development of the disease, in contrast 
to the proliferation of PASMC in vitro induced by EGF alone. Currently however, we do not 
have data that could precisely explain the discrepancy in the efficacy of the EGFR inhibitors in 
MCT-injected rats and this warrants additional studies in the future.  
Experiments performed in our group[37] on a mouse model of hypoxia-induced 
pulmonary hypertension demonstrated, in contrast to the significant response to gefitinib and 
erlotinib seen in the MCT model, the lack of efficacy of any of the three EGFR inhibitors in 
reverting the disease, as neither of them could reduce the hemodynamic parameters or delay the 
remodeling process. The presence of redundant tyrosine kinase receptors and the constitutive 
activation of downstream mediators[14;19], which are suggested mechanisms for the development 
of failure or resistance to anti-EGFR treatment in cancer, can represent a possible explanation. 
Chakravarti et al. have previously demonstrated that the redundant signaling through insulin 
growth factor receptor (IGF1R), even in the presence of EGFR inhibition, maintains the 
activation of critical pathways for survival of glioblastoma cells[23]. Furthermore, vascular cells 
including PASMCs proliferate in response to hypoxia and this proliferative response involves 
the action of growth factors such as PDGF, FGF and EGF[33;73;90;160] suggesting that multiple 
growth factors activate their receptor TKs leading to vascular SMC proliferation and survival. 
The redundancy of growth factors and RTK signaling having overlapping functions and activity 
during chronic hypoxia may explain the failure of the EGFR antagonists to yield beneficial 
results in chronically hypoxic mice. 
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Figure 25. Proposed mechanism of action for EGFR inhibitors gefitinib, erlotinib and lapatinib (adapted after 
Bianco R.  et al., 2007[13]). The black arrows symbolize the induction of intracellular signaling pathways  and the 
red lines indicate the inhibitory effect of EGFR inhibitors in the cell (continuous lines for demonstrated events, 
dashed lines for postulated mechanisms). 
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IV.3. Clinical perspective  
 
To our knowledge, the present study is the first to assess and compare in a head-to-head 
experiment the efficacy of three clinically approved, cancer treatment effective EGFR inhibitors 
in experimental PAH. Also, it represents a translational research study focusing on the role of 
EGFR signaling inhibition in a well accepted animal model of pulmonary hypertension.  
In this study we proved the therapeutic efficacy of the EGFR antagonists gefitinib and 
erlotinib in improving not only the hemodynamic and histological features of pulmonary 
hypertension, but also the symptoms of the disease in MCT rats, when chronic treatment was 
initiated after the complete establishment of the disease. Interestingly, another EGFR1/ErbB2 
inhibitor, lapatinib, failed to demonstrate a significant efficacy in reverting pulmonary 
hypertension in the same animal model, when used daily at the highest tolerable dose. Also, the 
complete lack of efficacy of any of these inhibitors in the hypoxia-induced PH in mice 
demonstrates the partial therapeutic effect of EGFR inhibition depending on the animal model, 
the inhibitors and doses used. Furthermore, it suggests the fact that these two animal models do 
not have a common pathomechanism regarding the involvement of the EGF pathway.  
Therefore, since neither the monocrotaline nor the hypoxic model can fully mimic the 
human condition, the investigation of these inhibitors in other animal models of PH as well as a 
complete study on the survival benefits and maintainance of effects in time would be helpful in a 
preliminary experimental phase and could help confirming the relevance of these findings to 
clinical PAH.  
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V. SUMMARY 
 
Pulmonary arterial hypertension (PAH) is a severe condition associated, if left untreated, 
with a poor prognosis and a high mortality rate. Pulmonary vascular remodeling, the main cause 
and the key pathological feature of PAH, subsequently causes the progressive increase of 
pulmonary vascular resistance and pulmonary arterial pressure, leading to right ventricular 
failure and death. In the development of the cellular events leading to lung arterial remodeling, 
like increased proliferation, resistance to apoptosis and migration of pulmonary vascular cells, 
the involvement of growth factors such as platelet-derived growth factor (PDGF) and epidermal 
growth factor (EGF) has been suggested.  
Recent studies showed that inhibition of EGFR by the dual EGFR/HER2 inhibitor 
PKI166, a test compound, could mediate vascular SMC apoptosis and improve survival in 
monocrotaline (MCT)-treated rats, suggesting the possible therapeutic effect of EGF pathway 
blockage. In the light of these results, our study has aimed to investigate in the MCT model of 
PAH the therapeutic efficacy of chronic administration of three EGFR inhibitors which have the 
advantage of being already approved for use in the clinical practice for cancer patients. Our 
results have shown that in rats with established PH, gefitinib and erlotinib dose-dependently 
reduced RVSP and right heart hypertrophy, and, in addition, improved the medial wall thickness 
and muscularization levels of small pulmonary arteries. Furthermore, our results demonstrate a 
positive average bodyweight change, an improvement of the distress score and an increase of 
survival after two weeks of treatment in both gefitinib and erlotinib groups, with gefitinib having 
the most potent effect. Surprisingly, in contrast with gefitinib and erlotinib, which are EGFR1 
antagonists and exhibited a partial effect, lapatinib, a dual EGFR/HER2 inhibitor, provided the 
least significant therapeutic benefit, as demonstrated by the development of vascular 
remodeling, right heart hypertrophy and by the negative impact on bodyweight, distress score 
and survival in treated rats. 
To our knowledge, this is the first study to investigate the role of EGFR signaling 
inhibition using three clinically approved small-molecule inhibitors in an established animal 
model of PH, in a head-to-head experiment. Our findings may represent the basis for further 
investigation and for the development of new therapeutic directions, with potential direct clinical 
application in the field of the human PAH treatment.  
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VI. ZUSAMMENFASSUNG 
 
 
Die pulmonale Hypertonie ist eine Erkrankung der Lungengefäße, die durch Erhöhung 
der Nachlast zu einer Rechtsherzhypertrophie führt. Der strukturelle Umbau der 
Pulmonalarterien betrifft alle Schichten der Gefäßwand. In der Intima kommt es zur 
Proliferation von Endothelzellen und zu einer Ausbildung einer Neointima. In der Media weisen 
glatte Muskelzellen eine Resistenz auf den natürlichen Zelltod (Apoptose) auf und sind durch 
erhöhte Migartion und Proliferation charakterisiert. In der Adventita werden Fibroblasten zur 
Kollagenbildung aktiviert. Auf all diesen Ebenen wird die Beteiligung von Wachstumsfaktoren 
wie Platelet-Derived Growth Factor (PDGF) oder Epidermal Growth Factor (EGF) vermutet, die 
über nachgeschaltete Signalwege Proliferation, Migration und Apoptoseresistenz vermitteln.  
Es konnte gezeigt werden, dass die Hemmung des EGF Rezeptors durch die 
Testsubstanz PKI166, einem dualen EGFR/HER2-Hemmer, den strukturellen Gefäßwandumbau 
der Pulmonalarterien verbessert und das Überleben pulmonal hypertensiver Monocrotalin 
(MCT) Ratten erhöht. Es lässt sich somit ein möglicher therapeutischer Einsatz der EGF-
Blocker ableiten. Angesichts dieser Resultate hat unsere Studie darauf abgezielt, im MCT-
Modell der pulmonalen Hypertonie die therapeutischen Effekte von drei bereits klinisch 
zugelassenen EGFR-Hemmern zu untersuchen, um eine schnelle Translation in die Klinik zu 
erreichen. Wir konnten in dem MCT Modell der PH eine dosisabhängige Senkung des 
rechtsventrikulären Drucks und der Rechtsherzhypertrophie durch die EGFR1 Hemmstoffe 
Gefitinib und Erlotinib zeigen. Histologisch wurde eine Abnahme der mittleren 
Gefäßwandstärke sowie eine Reduktion der Muskularisierung von kleinen Lungenarterien 
gezeigt. Auch die Proliferation von Gefäßzellen (im wesentlichen in der Media und Adventitia 
lokalisiert) konnte gesenkt werden. Im Gegensatz dazu zeigte der duale EGFR/HER2 
Hemmstoff Lapatinib keine Effektivität in diesem klinisch relevanten Tiermodell der PH, was 
eventuell auf die Hemmeigenschaften dieser Substanz zurück zu führen ist.  
Da diese Substanzen bereits zur Therapie verschiedener Krebserkrankungen zugelassen 
sind, könnte eine weitere klinische Entwicklung von EGFR Hemmstoffen erfolgen.  
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VIII. ABBREVIATIONS AND ACRONYMS 
 
5-HTT 5-hydroxytryptamine (serotonin) transporter 
ALK-1 Activin receptor-like kinase type 1 
Ang-1 Angiopoietin-1 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
Bcl-2 family  B-cell lymphoma family of proteins involved in apoptosis 
bFGF Basic fibroblast growth factor 
BMPR II  Bone morphogenetic protein receptor type II 
BSA Bovine serum albumin 
BW Bodyweight 
Ca2+ Calcium ion 
c-FLIP Cellular FLICE-like inhibitory protein (a negative regulator of death 
receptor-induced apoptosis) 
c-Fos  A cellular proto-oncogene belonging to the immediate early gene 
family of transcription factors 
CI Cardiac index 
cmH2O Centimeters of water (1 cmH2O= the pressure exerted by a column 
of water of 1 cm in height at 4 °C) 
CNS Central nervous system 
CO Cardiac output 
CO2 Carbon dioxide 
CTEPH Chronic thromboembolic pulmonary hypertension 
C-terminal end Carboxy-terminal end 
CYP3A4, CYP3A5 Cytochromes P450 3A4 and 3A5, respectively 
DAB  Diaminobenzidine 
DNA Deoxyribonucleic acid 
EGF Epidermal growth factor 
EGFR1 (ErbB1, HER1), EGFR2 (ErbB2, 
HER2/c-neu), EGFR3 (ErbB3, HER3), 
EGFR4 (ErbB4, HER4) 
Epidermal growth factor receptors 1,2,3 and 4 
ErbB Erythroblastic Leukemia Viral Oncogene Homolog 
ET Endothelin  
ET-A, B Endothelin receptors A,B 
FDA Food and Drug Administration 
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FiO2 Fraction of inspired oxygen in a gas mixture. 
FPAH Familial pulmonary arterial hypertension 
FSH Follicle-stimulating hormone 
g Gram (unit of mass) 
GABA Gamma-aminobutyric acid 
Gq Phospholipase C- coupled Gq protein 
H2O2 Hydrogen peroxide 
Hb Hemoglobin 
HB-EGF Heparin-binding EGF-like growth factor 
HCl Hydrogen chloride 
HIF-1α Hypoxia-inducible transcription factor 1 alpha 
HIV Human immunodeficiency virus 
IGF Insulin-like growth factor 
IGF1R Insulin-like growth factor 1 receptor 
IgG Immunoglobulin G 
IL-1, 6 Interleukin 1,6 
IOP Index of proliferation 
IP3 Inositol trisphosphate or inositol 1,4,5-trisphosphate 
IPAH Idiopathic pulmonary arterial hypertension 
LV Left ventricle wall 
MAPK Mitogen-activated protein (MAP) kinases 
Mcl-1 Induced myeloid leukemia cell differentiation protein  
MCT Monocrotaline 
MCT-P Monocrotaline pyrrole 
min Minute (unit of measurement of time) 
mmHg Millimeter of mercury (a unit of pressure) 
mRNA Messenger RNA 
MWT Medial wall thickness 
N2 Nitrogen gas 
NaCl Sodium chloride 
NaOH Sodium hydroxide 
NF-KB Nuclear Factor-KappaB (nuclear factor kappa-light-chain-enhancer 
of activated B cells)- transcription factor 
NO Nitric oxide 
NSCLC Non-small cell lung carcinoma 
NYHA The New York Heart Association Functional Classification 
O2 Oxygen gas 
PAH Pulmonary arterial hypertension 
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PAI-1 Plasminogen activator inhibitor-1 
PaO2 Partial pressure of oxygen in arterial blood 
PAP Pulmonary arterial pressure 
PASMC Pulmonary artery smooth muscle cells 
PBS Phosphate buffered saline 
PCH Pulmonary capillary hemangiomatosis 
PCNA Proliferating cell nuclear antigen 
PDE-5 inhibitors Phosphodiesterase type 5 inhibitors 
PDGF (A,B,C,D) Platelet derived growth factor (A,B,C,D) 
PEEP Positive end-expiratory pressure 
pH A measure of the acidity or basicity of a solution 
PI3K Phosphoinositide 3-kinase 
PIP2 Phosphatidylinositol 4,5-bisphosphate 
PKC Protein kinase-C 
PLCγ Phospholipase C gamma 
PPHN Persistent pulmonary hypertension of the newborn 
PVOD Pulmonary veno-occlusive disease 
QT interval A measure of the time between the start of the Q wave and the end 
of the T wave in the heart’s electrical cycle 
RANTES Regulated upon activation, normal T-cell expressed and secreted (a 
member of the interleukin-8 superfamily of cytokines) 
ROS Reactive oxygen species 
RPM Rotations per minute 
RT Room temperature 
RTK Receptor tyrosine kinase 
RV Right ventricle wall 
RVSP Right ventricular systolic pressure 
S Interventricular septum 
SAP Systemic arterial pressure 
SEM Standard error mean 
SMCs Smooth muscle cells 
STAT- 1, 3 Signal Transducers and Activator of Transcription –1,3 
(members of the Signal Transducers and Activators of Transcription 
family of transcription factors) 
TGF α, TGF ß  Transforming growth factor –alpha and beta  
TK Tyrosine kinase 
TK-I Tyrosine kinase inhibitors 
TN-C Tenascin-C 
ABBREVIATIONS AND ACRONYMS 
____________________________________________________________________________________ 
 
New  Therapeutic Strategies for the Treatment of Experimental Pulmonary Hypertension:  
Role of the Epidermal Growth Factor 
 
85
t-PA Tissue plasminogen activator 
TPR Total pulmonary vascular resistance index 
TSR Total systemic vascular resistance index 
VEGF Vascular endothelial growth factor 
VSMC Vascular smooth muscle cells 
α-actin Alpha-actin (muscle protein localized in myofibrils) 
µl A microliter (one millionth of a liter) 
µm A micrometer (one millionth of a metre) 
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